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Thesis Outline 
 
More than two-thirds of patients diagnosed with urothelial cell carcinoma (UCC) present 
with superficial tumors in the bladder. Due to a high risk of tumor recurrence, the 
follow-up of these patients after primary tumor resection is characterized by frequent 
examinations of the bladder with invasive cystoscopy. The need for a stringent follow-up 
scheme is further emphasized by the 10% risk of developing a more advanced disease 
stage with a concomitant significant decreased survival. The clinical management of 
patients with superficial UCC, therefore, represent a high burden to the patient, to 
treatment expenditure and, consequently, to the general society. Accurate prediction of 
the clinical course of patients with superficial UCC could individualize treatment and 
reduce the number of invasive and costly cystoscopies in a substantial group of patients. 
This thesis describes the analysis of molecular markers for their ability to predict the 
clinical course of patients with UCC. In the chapters 2, 3 and 4, the evaluation of three 
different markers in a cohort of patients with superficial and invasive UCC is described. 
Their relationship with the clinical parameters tumor recurrence, tumor progression and 
survival is investigated. The results from these studies, especially those from chapter 2, 
led us to subsequently focus on the prediction of tumor recurrence in patients with 
superficial UCC. This is described in the chapters 5, 6 and 7. These chapters evaluate 
the performance of molecular markers for the identification of patients with Ta tumors 
and short or long recurrence-free periods. A number of genes selected from the literature 
is validated, and a comparison between protein expression and mRNA expression is 
made. Finally, chapters 8 and 9 describe the utility of bladder washings in the prediction 
of the time to tumor recurrence in patients with superficial UCC. Bladder washings 
reflect the molecular biological state of the bladder and are easily collected prior to 
surgery. They may have an added value  compared to tumor tissue, because they cover 
the entire urothelium and might constitute a useful addition or a possible alternative to 
tumor tissue in the study of molecular prognostics in patients with UCC. 
After a summary, the thesis concludes with a general discussion that highlights 
important aspects of research regarding the prognostic utility of molecular markers. 
Also, a point of attention more specific to research concerning the prediction of the time 
to tumor recurrence in patients with UCC is addressed. 
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1. Bladder Cancer Characteristics 
 
1.1 Epidemiology 
 
Worldwide, bladder cancer is the ninth most often diagnosed and the twelfth most often 
cause of death among all human cancers [1]. Approximately 350.000 patients are newly 
diagnosed with bladder cancer each year. The number is highest among the European 
and North American population, where 63% of all new cases occur. About 145.000 
patients will die of this disease each year [1]. With an annual prevalence of 1.1 million 
patients, bladder cancer is the seventh most common human cancer worldwide. The high 
prevalence is caused by the large group of patients that is diagnosed with superficial 
disease, which have a high chance of survival but may carry the disease for a long period 
of time. 
 In the Netherlands, about 4600 patients are diagnosed with bladder cancer each year, 
which makes it the sixth most often diagnosed cancer. Moreover, bladder cancer has the 
highest incidence among all cancer types regarding the diagnosis of patients with 
superficial disease. Men are more often diagnosed with bladder cancer (78% of cases) 
than women. The disease ranks ninth regarding cancer mortality, with an approximate 
1100 deaths annually. The number of patients diagnosed with bladder cancer in The 
Netherlands is expected to increase over the next years [2], while the mortality rate is 
predicted to decrease [3]. 
 
1.2 Disease Presentation 
 
Different forms of cancer may arise in the bladder. Of these, urothelial cell carcinoma 
(UCC) is by far the most frequently diagnosed form and comprises approximately 95% 
of all bladder tumors. UCC arises in the urothelium that lines the inside of the bladder, 
and all tumors originate from this layer of cells (Fig. 1). The tumors can be divided into 
two categories, designated superfical and (muscle) invasive. The superficial group 
consists of three tumor stages: Ta, T1 and CIS (carcinoma in situ). The growth of Ta 
tumors remains confined to the urothelium, although they may extend substantially into 
the bladder cavity. The T1 tumors are minimally invasive and invade the lamina proria. 
CIS presents as flat growing lesions, of which the growth is intially limited to the 
urothelium. These tumors, however, have a very high propensity to become muscle 
invasive. 
 The group of muscle invasive tumors can be divided into three categories called T2, 
T3 and T4. These three stages are distinguished from each other by the depth of organ 
invasion. All have invaded the bladder muscle, but T3 tumors will extend into the 
underlying layer of fat and T4 tumors protrude into other organs, like the prostate. The 
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Figure 1. Schematic re- 
presentation of the growth 
of bladder tumors at 
different disease stages 
(Ta-T4). Bladder invasion 
increases with increasing 
tumor stage. 
 
 
 
 
 
 
 
chance of concomitant metastasis increases with increasing tumor stage. 
 Besides the classification of the tumors into different stages, the tumors can also be 
subdivided into different categories of grade. Whereas stage refers to the depth of 
invasion, grade indicates the degree of de-differentiation, or abnormality, of the tumor 
cells compared to normal urothelial cells. The more undifferentiated, the more 
aggressive a tumor cell behaves. The least deviant from normal urothelial cells are the 
grade 1 (G1) tumor cells. These are usually associated with stage Ta tumors. Subsequent 
grades are G2 and G3. Grade 2 tumor cells are medium aggressive and are mostly found 
in stage Ta and T1 tumors. The highest grade tumor cells are associated with the 
invasive tumors and some aggressive Ta and T1 tumors. The flat growing CIS lesions 
are also mainly comprised of G3 tumor cells. 
 
1.3 Natural History 
 
At the time of diagnosis, about 70-80% of the patients presents with superficial bladder 
cancer. This includes Ta, T1 and CIS tumors. The remaining group shows muscle 
invasive tumors, of which a small number will also have concomitant metastasis. The 
choice of initial treatment depends on the type of tumor a patients is diagnosed with. 
 Patients with superficial UCC are initially treated by transurethral resection of the 
tumor (TURT). Afterwards, the urologist may decide to apply adjuvant intravesical 
treatment in order to eradicate remaining tumor cells and reduce the recurrence rate. 
Patients with muscle-invasive UCC are treated by cystectomy, which means the 
complete removal of the bladder. Again, the urologist may decide to treat the patient 
additionally with systemic chemotherapeutics to kill remaining tumor cells and reduce 
the risk of tumor metastasis. 
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 After initial treatment, patients with UCC exhibit different patterns in the course of 
the disease. Those diagnosed with superficial Ta and T1 UCC, have an approximate 
risk of 70% of developing recurrences within the first five years after primary surgery. 
This risk is highest among patients with T1 tumors. Moreover, an approximate 40% of 
patients diagnosed with Ta tumors remains recurrence-free for 5 years. The group of 
patients with superficial UCC has an approximate 10% risk of developing muscle 
invasive tumors, for which patients with T1 UCC are at highest risk. Most of the patients 
with superficial tumors are still alive five years after initial treatment. The five-year 
survival rate for these patients is as high as 85% [4]. The patients diagnosed with T1 
tumors are at the greatest risk of dying of UCC within 5 years. Patients with superficial 
Ta or T1 tumors diagnosed with concomitant carcinoma in situ display an increased risk 
of recurrence and progression compared to those without CIS [5]. 
 The patients diagnosed with muscle-invasive disease are tightly monitored after 
cystectomy, since they are at high risk of developing metastatic disease. The survival 
chance decreases with increasing tumor stage and with concomitant metastasis [6]. For 
instance, patients with T2 UCC treated by cystectomy have a 5-year survival chance of 
approximately 70%, whereas those that already present with metastases, have a 
significantly decreased chance of survival of 10-15% [6]. 
 
2. Prediction of Tumor Recurrence in Patients with Superficial UCC 
 
2.1 Clinical Problem 
 
The clinical management of the large group of patients with superficial UCC represents 
an important burden to the patient, the urologist and the general society. The high risk of 
tumor recurrence for this group necessitates frequent examination of the bladder, 
generally once every 3-4 months. The urge for the urologists to follow the patient 
carefully is further encouraged by the risk of progression to muscle-invasive disease, 
which has a concomitant decreased survival [7]. Progression may be indicated by early 
recurrence [8], which emphasizes the need for regular bladder examination. The 
mainstay for the detection of primary or recurrent tumors in the bladder is cystoscopy, 
often supplemented by cytology. It is an invasive procedure, which renders cystoscopy 
the major source of the high patient burden. Since cystospcopy is also costly and patients 
with superficial UCC often receive additional treatment after surgery, the clinical 
management of these patients also represents a high burden to treatment expenditure [9]. 
It would, therefore, be of great help to both the patient as well as the urologist if the time 
to tumor recurrence after surgery could be predicted accurately. The urologist may then 
be able to identify patients who need early control cystoscopy or safeguard the patients 
who remain recurrence-free for several years from unnecessary control cystoscopies. 
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Additionally, accurate prediction of early tumor recurrence may facilitate the decision to 
treat certain patients more aggressively to prolong the recurrence-free period. 
  
2.2 The Role of Pathology 
 
Through the years, urologists have gained insight into the general clinical course of 
patients with Ta and T1 UCC. The pathological staging and grading of the resected 
tumors has played an important part in this. To support the identification of the different 
tumor types, a universal bladder tumor classification system was formulated to 
distinguish between superficial and invasive tumors [10], and between different tumor 
grades [11]. The tumor classification provides valuable information regarding the time to 
tumor recurrence [12, 13]. In addition, the identification of pathologically defined 
subgroups within Ta and T1 tumors may also help [14, 15]. One of these studies [15] 
applied the adapted version of the universal bladder tumor grading system [16], which 
was introduced to distinguish between histologically defined subgroups of Ta tumors 
and improve disease prognosis. However, the reproducibility and prognostic utility of 
the new Ta subclassification have been questioned [17, 18]. In addition to the 
classification of the different tumors to assist the prediction of the clinical course, other 
factors like tumor multiplicity and tumor size may also provide prognostic information 
[19, 20]. A recent study combined six important pathological parameters and constructed 
risk tables that allow the urologist to obtain an indication of a patients’ individual risk of 
recurrence or tumor progression [21]. These factors were number of tumors, prior 
recurrence rate and tumor size as predictors of recurrence, and tumor grade, T category 
and the presence of CIS as predictors of progression. Although the pathological 
parameters are relatively accurate on a group level, they have important drawbacks. 
 The urologist depends on the accurate determination of tumor stage by the 
pathologist, who needs a tumor specimen that also includes surrounding tissue, like 
lamina propria and muscle, to judge the depth of invasion. Several studies have shown 
high disagreement in the characterization of the same tumor specimen by different 
pathologists [17, 22-25]. This incorrect staging may result in over- or underestimation of 
the risk of recurrence, which in turn may affect the choice of patient treatment. The 
inclusion of more characteristics, like tumor grade, tumor multiplicity and tumor size, 
does not simplify treatment decision-making. Additionally, the pathological 
characteristics provide the urologist with a general picture regarding recurrence 
prognosis for the different patient groups. It is, however, still difficult to estimate the risk 
of recurrence for each patient individually. Therefore, a more accurate and standardized 
test that could supplement or possibly replace the current pathological standards, that are 
used for the prediction of recurrence, is appreciated. 
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2.3 Molecular Markers 
 
At the end of the last century, scientist began to map the molecular biological changes 
occuring during tumorigenesis. Compared to normal cells, tumor cells displayed 
increased or decreased protein or mRNA expression levels and numerous alterations at 
the DNA level. These so-called molecular markers provided information with respect to 
the clinical course of patients with cancer [26]. The molecular biological alterations have 
also been studied in patients with superficial UCC. This revealed a relationship with the 
time to tumor recurrence for a number of molecular markers. These have been depicted 
in Table 1, in which only statistically significant (p<0.05) relationships between 
molecular markers and tumor recurrence have been included. Adjuvant treatment has 
been mentioned because it may affect the recurrence-free period after tumor resection 
[27]. Therefore, a marker that has been studied in patients who did not receive adjuvant 
treatment may provide a more representative picture with regard to the prediction of 
recurrence than a marker influenced by additional treatment. Different methods have 
been applied to detect changes in gene mRNA or protein expression and chromosomal 
DNA alterations in tumor tissue, serum, urinary cells and bladder washes. The markers 
have been categorized according to protein expression, mRNA expression and DNA 
alterations. 
 
2.3.1 Protein Expression 
 
Cell Cycle Regulators 
The prognostic value of cell cycle regulators has been investigated intensively in bladder 
cancer. Important regulators like p53, pRB and p21 have been implicated in bladder 
tumor recurrence, but mainly in patients with advanced disease [28-31]. Their role in 
predicting superficial tumor recurrence is limited [32-35]. Other cell cycle regulators, 
like p27 and cyclin D1, show a relationship between their protein expression level and 
early tumor recurrence [36-38], although contradictory results also exist [37, 39]. 
Clearly, the role of cell cycle regulators has not been firmly established in the prediction 
of tumor recurrence in patients with superficial bladder cancer. 
 
Ki-67 
The Ki-67 antigen is strongly associated with cellular proliferation. It has often been 
targeted for the assessment of the proliferative activity of bladder tumor cells, and 
relating the staining 
index with tumor recurrence. Many studies have shown a correlation between a high 
staining index and early tumor recurrence in patients with superficial bladder cancer [37, 
40-46]. This role in recurrence prediction seems independent of adjuvant treatment 
[Table 1]. 
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Table 1: Molecular markers for tumor recurrence prediction in patients with 
superficial bladder cancer: Study characteristics 
                     No. of patients 
               Univariate/   with adjuvant 
Marker  Ref. No. Patients  Material  Multivariatea   treatment (%) 
Protein Expression 
p27   [36]  56    Tissue   Univariate     ?b  
    [38]  96    Tissue   Multivariate    96 (100) 
Cyclin D1  [37]  159   Tissue   Multivariate    15 (9) 
Ki-67/MIB-1 [37]  159   Tissue   Multivariate    82 (52) 
    [40]  104   Tissue   Multivariate    6 (6) 
    [41]  240   Tissue   Multivariate    81 (34) 
    [42]  62    Tissue   Multivariate    30 (48) 
    [43]  159   Tissue   Multivariate    15 (9) 
    [44]  140   Tissue   Multivariate    114 (81) 
    [45]  93    Tissue   Multivariate    ? 
    [46]  270   Tissue   Multivariate    66 (24) 
Survivin  [49]  20    Tissue   Univariate     ?b   
    [50]  88    Tissue   Multivariate    ? 
Centrosome [52]  43    Tissue   Multivariate    7 (16) 
 amplification 
sFasL   [53]  85    Serum   Univariate     ? 
OPG   [54]  136   Serum   Univariate     ? 
CD44   [55]  241   Tissue   Univariate     62 (26) 
KRT20   [56]  120   Tissue   Univariate     56 (47) 
KAI1   [57]  87    Tissue   Multivariate    82 (94) 
mRNA Expression 
Survivin  [58]  26    Bladder wash Univariate     13 (50) 
     [59]  17    Tissue   Univariate     11 (65) 
    [60]  21    Tissue   Univariate     8 (38) 
VEGF   [62]  55    Tissue   Multivariate    0 (0) 
Livin   [61]  30    Tissue   Univariate     18 (60) 
Bcl2/Bax  [61]  30    Tissue   Univariate     18 (60) 
Bcl-XL   [61]  30    Tissue   Univariate     18 (60) 
H19   [63]  48    Tissue   Univariate     ? 
MMP-9  [64]  51    Tissue   Multivariate    0 (0) 
TIMP-2  [64]  51    Tissue   Multivariate    0 (0) 
CD44   [65]  68    Urinary cells Multivariate    ? 
DNA Alterations 
FGFR3   [67]  57    Tissue   Multivariate    ? 
  mutation 
Microsatellite [68]  133   Tissue   Multivariate    ? 
 analysis  [69]  46    Tissue   Univariate     ? 
    [70]  24    Tissue   Univariate     ? 
Methylation [71]  55    Tissue   Multivariate    ? 
hOGG1  [72]  77    Tissue   Multivariate    ? 
genotype 
aNo statistical correction (Univariate) or correction (Multivariate) for classical prognostic variables. Statistical 
significance after multivariate analysis indicates that the marker is an independent prognostic factor. 
b? = unknown if adjuvant treatment has been given, or the number of patients that actually received it. 
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Survivin 
Survivin was discovered at the end of the last century [47]. It is an anti-apoptosis gene, 
which is upregulated in many human cancers [48]. Soon after its discovery, survivin  
protein expression was investigated in patients with superficial bladder tumors by 
immunohistochemistry. Absence of survivin protein predicted a prolonged tumor-free 
period [49]. In a multivariate analysis, Ku et al. showed early recurrence in patients with 
Ta and T1 tumors that displayed high levels of survivin protein [50]. The determination 
of a standard protein expression threshold for the distinction between patients with early- 
and late-recurring tumors would enhance its clinical utility. 
 
Centrosome Hyperamplification 
Centrosomes are protein complexes that play an important role in the control of cell 
division. Tumor cells, in which cell division is derailed, often display amplification of 
the centrosomes and concurrent genome instability [51]. Patients with superficial bladder 
cancer and centrosome hyperamplification (CH) experienced reduced recurrence-free 
intervals compared with CH-negative patients [52]. 
 
Proteins Expressed in Serum 
Analysis of serum protein expression by ELISA in relation to tumor recurrence has also 
proven successful. Elevated levels of soluble FasL, a ligand involved in apoptotic 
signaling, in serum of patients with Ta tumors indicated early tumor recurrence [53]. The 
same group investigated serum osteoprotegerin (OPG) levels in another group of patients 
[54]. Increased levels of OPG identified early recurring tumors in the group of Ta and T1 
tumors. 
 
Other Protein Markers 
A number of additional markers, including CD44, cytokeratin 20 and KAI1, has been 
investigated in single studies. Their level of protein expression shows a relationship with 
the time to tumor recurrence in patients with superficial UCC [55-57]. Additional 
experiments need to verify the predictive potential in other patient cohorts. 
 
2.3.2 mRNA Expression 
 
Survivin 
A relationship between survivin mRNA expression and tumor recurrence has been 
investigated in tumor tissue and bladder washings from patients with superficial Ta/T1 
tumors. In both tissue as well as in cells from bladder washings, high survivin mRNA 
expression indicated early tumor recurrence [58-60]. Weikert et al. detected this 
correlation only in Ta tumors, whereas Schultz et al. studied both Ta and T1 tumors. 
None of the studies showed a relationship with tumor recurrence independent of clinical 
variables. Only one report, performed by Gazzaniga et al., contradicted the findings of 
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the three studies [61]. Discrepancies in the results may be explained by the detection of 
different survivin splice variants or variability in the percentage of tumor cells of the 
selected tissues. 
 
Vascular Endothelial Growth Factor 
One of the first studies that investigated mRNA expression of a molecular marker and 
relating it to the time to tumor recurrence was conducted by Crew et al. [62]. They 
investigated expression of the vascular endothelial growth factor (VEGF). It plays an 
important role in angiogenesis, a process commonly associated with actively growing 
tumors. In superficial T1 bladder tumors, VEGF mRNA expression was an independent 
prognostic factor for early tumor recurrence [62]. These results have thus far not been 
verified in additional reports. 
 
Genes Involved in Apoptosis 
Prevention of apoptosis during tumorigenesis promotes tumor cell survival and the genes 
involved in this process may provide valuable prognostic information. In a univariate 
analysis, Gazzaniga et al. studied mRNA expression of a number of genes with either 
pro- or anti-apoptotic properties [61]. They reported that high expression of the anti-
apoptotic gene Livin (isoform α), an increased Bcl-2/Bax ratio and increased expression 
of the Bcl-X isoform Bcl-XL indicated a shorter relapse-free period. 
 
Other mRNA Markers 
Several additional studies describe a relationship between elevated mRNA 
expression and the time to tumor recurrence for a number of markers, including the 
imprinted gene H19, matrix metalloproteinase 9, tissue inhibitor of metalloproteinase 2 
and the CD44 isoform CD44v8-10 [63-65]. Interestingly, the latter study measured 
mRNA expression in urinary cells, which may offer the opportunity to develop a non-
invasive test. Since mRNA yield form urinary cells is generally poor, it remains to be 
investigated whether this test is solid and can be reproduced by other laboratories. 
 
2.3.3 DNA Alterations 
 
FGFR3 Mutation 
The discovery of activating mutations in the fibroblast growth factor 3 gene [66] 
initiated research regarding its prognostic value in bladder cancer. Van Rhijn et al. 
showed that patients with a mutated FGFR3 gene displayed a significantly decreased 
recurrence rate compared with non-mutated patients [67]. Since mutation detection is a 
relatively simple and  qualitative test, the determination of the FGFR3 mutation may 
prove a valuable marker in recurrence prediction. 
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Microsatellite Analysis 
Microsatellites are small polymorphic DNA sequences that are frequently altered in 
tumor cells. The alterations can be visualized by PCR amplification of the microsatellite 
and comparing the intensity ratios of the amplified alleles. Simoneau et al. investigated 
microsatellite alterations and showed that deletion of certain regions of chromosome 9 
indicates a shorter time to first recurrence [68]. Analysis of chromosomes 4, 8, 11 and 
17, revealed a significant association of the loss of two regions on chromosomes 11 and 
17 with a decreased disease-free interval [69]. A more recent comprehensive analysis of 
microsatellite alterations also showed a relationship between DNA alterations and tumor 
recurrence [70]. 
 
Methylation 
A more recently discovered DNA alteration is aberrant methylation of gene promoters. 
This epigenetic event influences gene activity and occurs frequently in tumor cells. Tada 
et al. studied the methylation pattern of several genes in superficial bladder tumors [71]. 
Promoter hypermethylation of the death-associated protein kinase was significantly 
linked with early tumor recurrence. The predictive accuracy of such a test may be 
increased by determining the methylation pattern of a panel of genes. This, however, 
adds to the complexity of the test and hampers routine use. 
 
hOGG1 Genotype 
The human 8-oxoguanine DNA glycosylase 1 gene (hOGG1), is involved in DNA 
damage repair. Kim et al. investigated the influence of two polymorphisms in hOGG1 on 
the recurrence rate in Korean patients with superficial bladder tumors [72]. They showed 
that patients that carry one of the two polymorphisms, more frequently experienced 
recurrences compared to patients with the wild-type gene. To date, the hOGG1 genotype 
has only been investigated amongst Koreans. Therefore, it should be investigated for 
other populations to estimate its utility in recurrence prediction. 
 
2.4 Advances in the Discovery of Molecular Markers 
 
In recent years, several techniques have been developed to further map the molecular 
biological changes occurring during bladder tumorigenesis on a larger scale. These 
sophisticated techniques are able to study alterations of large numbers of molecular 
markers in one experiment. This may result in the discovery of panels of markers that 
may improve, a.o., the prediction of tumor recurrence in patients with superficial UCC. 
Recent studies show that the combination of only two or three markers already improves 
disease prognosis substantially [73, 74]. This seems encouraging for the further 
improvement of the prediction of tumor recurrence when even more markers are studied 
simultaneously. 
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 One of the techniques that investigates the alteration of thousands of genes in a single 
tumor in one experiment is cDNA microarray [75]. It determines gene mRNA 
expression and has proven an ideal tool for the discovery of new molecular markers 
involved in bladder cancer [76-78]. Interestingly, in the study conducted by Dyrskjot et 
al., a panel of 26 genes was identified that distinguished between patients with Ta UCC 
and short or long recurrence-free periods [76]. Other techniques evaluate protein 
expression on a large scale. One of these, called tissue microarray, has also revealed a 
number of interesting molecular markers [79-81]. These protein arrays could also be 
helpful in validating the results from cDNA microarray experiments, or vice versa. 
Differences in protein expression between healthy and cancerous tissues can also be 
assessed by 2D-gel electrophoresis and has yielded interesting prognostic markers [82, 
83]. Finally, the detection of DNA alterations occurring during bladder tumorigenesis 
using single-nucleotide polymorphism arrays or array-based comparative genomic 
hybridization, also provides valuable prognostic information [84-87]. The mapping of all 
these molecular changes could eventually lead to the identification of a panel of 
molecular markers capable of accurately predicting tumor recurrence in patients with 
superficial UCC. Ultimately, a significant reduction of follow-up cystoscopies could be 
achieved in combination with a more tailored treatment of patients. 
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Abstract 
 
Background: Expression of the inhibitor of apoptosis protein survivin is upregulated in 
many tumors of epithelial origin and frequently shows a relationship with disease 
prognosis. Materials and Methods: We have investigated survivin mRNA expression in 
32 urothelial cell carcinomas by use of real-time quantitative PCR. Expression values 
were normalized to transcript levels of the housekeeping gene cyclophilin. Results: All 
bladder tumor tissues expressed survivin mRNA. Median normalized survivin mRNA 
expression values were 0.26 for superficial tumors (n = 17) and 0.78 for invasive tumors 
(n = 15). A significant relationship with increasing pathological stage (P < 0.001) and 
grade (p<0.001) was observed. Although survivin mRNA expression did not relate with 
disease progression or the patient survival period, patients with superficial bladder 
tumors and normalized survivin values over 0.26 had an increased risk of recurrence 
(log-rank test: p = 0.018). Conclusions: Our results suggest that quantitative 
measurement of survivin mRNA 1) can identify invasive and high grade urothelial cell 
carcinomas and 2) may be used as an indicator for early recurrence of superficial tumors. 
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Introduction 
 
Bladder cancer presents as urothelial cell carcinoma (UCC) in 95% of cases. About 30% 
of UCC is muscle invasive (T2-T4) at initial diagnosis and is treated with cystectomy. 
Superficial tumors are limited to the (sub)mucosa (Ta/T1) and are removed by 
transurethral resection, a less radical treatment. After transurethral resection, about 70% 
of the superficial tumors recur and some progress to muscle-invasive or metastatic 
disease (1-3). When the prognosis of UCC's can be accurately predicted, the urologist 
may adapt patient treatment at a time when the disease is still curable. 
Since molecular alterations underlie progression of superficial bladder tumors to high 
grade and invasive lesions, detection of these changes may provide prognostic 
information. Next to DNA alterations, for instance in the TP53 (4) and RB genes (5, 6), 
changes in mRNA expression levels show a relationship with progression. Examples are 
human chorionic gonadotropin (7), keratinocyte growth factor receptor (8), hTERT (9) 
and clusterin (10). Unfortunately, none of these markers is able to accurately predict the 
clinical course of UCC. 
Expression of the inhibitor of apoptosis (IAP) protein survivin (11) is upregulated in 
a number of cancers (12-16). Survivin is thought to promote cell proliferation by 
interfering with the apoptotic pathway and is expressed in embryonic and fetal organs 
(17,18), but not in fully differentiated tissues (11). These findings suggest that survivin 
may be a useful marker for prediction of prognosis in bladder cancer. 
We developed a real-time PCR assay and quantified survivin mRNA expression 
retrospectively in 32 bladder tumors. Expression data were compared with histo-
pathological and clinical follow-up parameters. 
 
Materials and Methods 
 
Patients and tissues 
Tumor tissues were obtained from 32 patients with UCC. Patients were hospitalized at 
the Canisius Wilhelmina Hospital or the University Medical Center Nijmegen, The 
Netherlands. Tumors were removed by transurethral resection or radical cystectomy and 
histo-pathological parameters were evaluated using the WHO criteria for determination 
of grade (19) and TNM classification for stage (20). All tissues were stored frozen at -
80°C. 
After transurethral resection, patients with superficial disease (Ta/T1, n = 17) were 
treated with additional intravesical instillations. Patients with invasive disease (n = 15) 
were treated with chemotherapy, radiotherapy or received no further treatment after 
surgery. Patients were followed clinically from the moment of tumor tissue collection. 
The mean follow-up period was 70.8 months (range 2 - 180 months). The survival period 
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was determined for all 32 patients. Progression (Ta/T1 to T2/T3) and time to first 
recurrence were only determined for the group of patients with superficial disease (n = 
17). 
 
RNA isolation and RT-PCR 
From all tissues, ten frozen 20 µM sections were disrupted in 1 ml Trizol (Life 
Technologies, Breda, The Netherlands) using a sterile pestle. Further steps followed the 
manufacturer's protocol. The percentage of tumor cells in the tumor tissues was 
investigated by hematoxylin and eosin staining of several 4 µM sections, taken at regular 
intervals between the 20 µM sections. Total RNA was only isolated from tissues 
containing >50% tumor cells. 
For each cDNA synthesis, 0.2-1.0 µg total RNA, 200 U Moloney murine leukemia 
virus (Life Technologies), 20 U RNasin (Promega, Madison, WI), 10 mM dithiothreitol, 
4.75 µM random hexamers, 600 µM deoxynucleotides and first strand buffer (Life 
Technologies) were mixed. RT-PCR steps were 10 min 20°C, 45 min at 42°C and 5 min 
at 95°C. 
 
Real-Time Quantitative PCR 
Survivin and cyclophilin mRNA were measured in each cDNA sample using ABI Prism 
7700 Sequence Detection System (PE Applied Biosystems). Primers and Taqman® probe 
for survivin (GenBank accession no. U75285) were chosen such that all three known 
splice variants (21) were detected: 5'-CTTTCTCAAGGACCACCGCA-3' (forward) and 
5'-GCCTCGGCCATCCGCT-3' (reverse). Optimized survivin mRNA PCR reactions 
contained 12.5 µl Taqman® Universal PCR Master Mix (PE Applied Biosystems), 100 
nM forward primer, 900 nM reverse primer, 150 nM Taqman probe (TET-5' 
CATTCAAGAACTGGCCCTTCTTGGAGG-3'-TAMRA) and 1 µl cDNA in a 25 µl 
reaction volume. In each sample mRNA expression of the housekeeping gene 
cyclophilin was measured to normalize survivin mRNA expression for sample-to-sample 
differences in RNA quality and reverse transcription efficiency. Cyclophilin mRNA 
PCR reactions contained 12.5 µl Taqman
®
 Universal PCR Master Mix, 1.25 µl Pre-
Developed Assay Reagent (PDAR) (PE Applied Biosystems) and 1 µl cDNA in a 25 µl 
reaction volume. Real-time PCR cycling parameters for both genes were as follows: 10 
minutes enzyme activation at 95°C followed by 40 two-step cycles of 30 seconds at 
95°C and 1 minute at 60°C. 
To express survivin and cyclophilin expression in absolute mRNA copy numbers, we 
constructed linearized plasmids containing either the survivin or the cyclophilin 
amplicon. In each real-time PCR assay a triplicate 5-log range calibration curve, 
containing 10 to 106 copies of either survivin or cyclophilin, was included. 
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Statistical analysis 
To detect a correlation between pathological tumor parameters and normalized survivin 
expression, median normalized survivin values were compared between superficial 
(Ta/T1) and invasive (T2/T3) UCC and between tumors with different differentiation 
grades (GI, GII, GIII). Differences were tested for statistical significance using the non-
parametric Mann-Whitney U test (stage and grade) and the Kruskal Wallis test (grade).  
The relationship between normalized survivin values (as a continuous variable) and 
bladder cancer specific survival was analyzed using a proportional hazards regression 
model, while adjusting for the prognostic effect of disease stage. 
In patients with superficial disease, a correlation of normalized survivin mRNA 
expression with time to first recurrence and with time to progression to muscle invasive 
disease was evaluated with survival analyses. Because of the small number of patients 
available for this analysis (n=17), we constructed Kaplan-Meier curves for patients with 
a normalized survivin expression below and above the median value and compared the 
curves with the log-rank test.  
The Statistical Package for Social Sciences (SPSS), release 10.0.7 (June, 2000), was 
used for analyses and statistical significance was indicated when the p-value was less 
than 0.05. 
 
Results 
 
Expression of survivin mRNA was quantified in 32 bladder tumor specimens with 
varying stage and grade. Also the housekeeping gene cyclophilin was measured to 
normalize survivin mRNA expression between samples. Typically, all tumor tissues 
expressed survivin mRNA. 
First we investigated whether normalized survivin mRNA expression levels could 
identify high grade (grade III) and/or muscle-invasive UCC's (Figure 1). The median 
normalized survivin mRNA expression values of superficial (stage Ta/T1) and invasive 
(stage T2/T3) tumors were 0.26 and 0.78, respectively, and differed significantly 
(p<0.001; Figure 1A). The median normalized survivin expression values for grade I, II 
and III tumors were 0.26, 0.40 and 0.85, respectively. Statistically significant differences 
were observed between grade I and III tumors (p=0.001) and between grade II and III 
tumors (p<0.001) (Figure 1B). A trend was observed between median values for grade I 
and II tumors (p=0.067). Additionally, using the Kruskal Wallis test, the median values 
of the three groups together differed significantly (p<0.001). 
Subsequently, a correlation between survivin expression and clinical follow-up 
parameters was investigated. While adjusting for the prognostic effect of disease stage, 
the normalized survivin expression values of all 32 patients were not predictive for 
bladder cancer specific survival. Further, the possible relationship between normalized 
survivin transcript levels and tumor progression or time to first recurrence was  
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Figure 1. Normalized expression of survivin mRNA in superficial (Ta/T1) versus invasive tumors 
(T2/T3) (A) and in GI, GII and GIII tumors (B). Normalized survivin = survivin mRNA copy 
number/cyclophilin mRNA copy number. 
 
investigated. For these analyses only patients with superficial tumors were included 
(n=17). In this group, five patients (29%) showed progression from superficial (Ta/T1) 
to invasive (T2/T3) UCC. No significant correlation was found between normalized 
survivin expression in the tumors and progression (log rank p-value = 0.49). However, 
normalized survivin levels did correlate with time to first recurrence. Patients with 
tumors with a normalized survivin expression above the median value of 0.26 (n=8) had 
a significantly higher risk of recurrence than patients with tumors with an expression 
below this value (p=0.018; Figure 2). The cumulative risk for both groups is 
approximately equal, but 7/8 (87%) patients in the high risk group had recurrences 
within one year. The median time to recurrence for the high risk group was 7 months 
versus 22 months for the low risk group. 
 
Figure 2. Kaplan-Meier risk of 
recurrence among 17 patients with 
superficial UCC. The dashed line 
represents the risk among patients 
with a normalized survivin value 
below the median value of 0.26 (n=9). 
The median time to recurrence for this 
group is 22 months. The solid line 
represents the risk among patients 
with a value above the median value 
of 0.26 (n=8). The median time to 
recurrence for this group is 7 months. 
The difference in risk is statistically 
significant: log rank p-value = 0.018. 
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Discussion 
 
In this study we have investigated normalized survivin mRNA expression as a 
prognostic marker in UCC. Real-time quantitative PCR was used as a technique to 
quantitate survivin mRNA in tumor tissues. 
Within tumor tissues survivin mRNA expression levels were elevated in high grade 
and invasive lesions. This suggested that survivin might play an important role in 
bladder cancer progression. Indeed, several other studies show that survivin expression 
correlates with clinical prognostic parameters for colorectal carcinoma (22), 
neuroblastoma (23, 24), adult T-cell leukaemia (25) and esophageal cancer (26, 27). 
Despite the clear correlation with pathological stage and grade, we could not find a 
relationship between survivin mRNA expression and bladder cancer specific survival. 
Neither could survivin transcript levels discriminate between patients with superficial 
disease who developed or did not develop progression to invasive UCC. The lack of a 
statistically significant relationship may be explained by the small number of patients 
that showed progression. A larger study will be necessary to determine whether survivin 
is an independent predictor of patient survival or progression to invasive disease in UCC. 
Interestingly however, a statistically significant relationship was present between 
survivin mRNA expression in superficial tumors and time to first recurrence. Previously, 
a similar relationship with tumor recurrences was found in bladder cancer by detecting 
the survivin protein (28). Our results suggest that patients with superficial disease, 
having a normalized survivin mRNA expression value above a defined threshold, may 
have an increased risk for developing recurrences. The most profound difference in risk 
of recurrence between the low and the high risk group was seen within one year after 
surgery. The median time to recurrence for the high risk patients was much shorter (7 
months) than that for patients with a normalized survivin expression value below the 
threshold (22 months). Even with the small number of patients in our study, the 
predictive value for time to recurrence was strong. Future studies should better define the 
threshold level for more accurate stratification. This stratification might help urologists 
in avoiding unnecessary and costly cystoscopies, since patients with a low risk for 
recurrence need a less stringent follow-up scheme. 
Altogether, our findings show that quantitative measurement of survivin mRNA in 
bladder tumor tissues can identify invasive and poorly differentiated UCC. More 
interesting, expression levels seem to be predictive of time to first recurrence in patients 
with superficial UCC. Although our results are preliminary, further efforts to investigate 
the potential of quantitative measurements of survivin mRNA as a prognostic marker are 
validated. Recently, survivin mRNA was detected in urine sediments obtained from 
patients with UCC using a qualitative RT-PCR (29). Our future studies will focus on the 
quantification of survivin mRNA in urine sediments as a non-invasive technique for 
prediction of tumor recurrence. Further, a larger study will be necessary to show a 
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correlation of elevated survivin mRNA expression with progression to muscle invasive 
disease and bladder cancer specific survival. 
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Abstract 
 
CDC91L1 (PIG-U) was recently discovered as a new oncogene in human bladder cancer 
and showed mRNA overexpression in 36% of primary bladder tumor tissues compared 
to normal urothelium. We further investigated CDC91L1 mRNA expression in 8 bladder 
cancer cell lines, 14 normal bladder tissues and 42 urothelial cell carcinomas by real-
time quantitative PCR. The prognostic value of CDC91L1 mRNA expression was also 
investigated. Surprisingly, only one (2.4%) tumor tissue showed overexpression 
compared to normal urothelium. No significant relationship of CDC91L1 mRNA 
expression with increasing pathological stage (p = 0.962) nor grade (p = 0.557) was 
observed. The median normalized CDC91L1 mRNA expression values were 0.19 for 
superficial tumors (n = 21) and 0.18 for invasive tumors (n = 21). Grade I, grade II and 
grade III tumors had median normalized expression values of 0.26, 0.18 and 0.33, 
respectively. The CDC91L1 mRNA expression level was not indicative of early tumor 
recurrence (log rank p-value = 0.1629), tumor progression (log rank p-value = 0.9307), 
nor overall and disease-specific survival (log rank p-values 0.9193 and 0.4710, 
respectively). Our results suggest, in contrast to the study by Guo et al., that the 
oncogene CDC91L1 is not overexpressed at the mRNA level in urothelial cell 
carcinomas and cannot be used to predict the course of the disease. 
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Introduction 
 
Bladder cancer is the ninth most common cancer worldwide (1). It usually presents as 
urothelial cell carcinoma (UCC). Most of the patients diagnosed with UCC have 
superficial tumors, designated Ta or T1, of which the depth of invasion is limited to the 
(sub)mucosa. Superficial tumors can be removed relatively easy by transurethral 
resection. However, in about 70% of the patients tumors recur after resection, which 
necessitates frequent examination of the bladder by cystoscopy. Furthermore, 
approximately 15% of the superficial tumors progress towards invasive and more 
aggressive disease. Accurate prediction of bladder tumor behavior may reduce the 
number of cystoscopies and individualize treatment. 
Currently, the major determinants of a patient's follow-up scheme and treatment 
procedures are tumor stage and grade. Since these parameters do not predict the course 
of the disease accurately enough, molecular markers are investigated for their prognostic 
value. Recent studies suggest that molecular biological changes during urothelial 
carcinogenesis provide additional or even better prognostic information (2-7). None of 
these markers is used as a clinical test yet. 
Recently, the gene CDC91L1 (PIG-U) was discovered as a new oncogene involved in 
human bladder cancer (8, 9). It was identified from a proband with a germline 
translocation t(5;20) (p15;q11), associated with familial urothelial carcinoma (10). Guo 
et al. showed that CDC91L1 displays oncogenic properties and is overexpressed in 22 of 
61 (36%) primary bladder tumors as compared with normal urothelium. These results 
indicate that CDC91L1 may have an important role in urothelial carcinogenesis and 
might also be an interesting therapeutic target. Besides, the expression of this gene may 
provide valuable prognostic information in bladder cancer. 
In this study, we aimed to confirm the results of Guo et al. CDC91L1 mRNA 
expression was measured in 14 normal bladder tissues, 42 human UCCs and 8 bladder 
cancer cell lines by real-time quantitative PCR. In addition, a relationship between the 
CDC91L1 expression data of the tumor tissues and clinical follow-up parameters was 
investigated. 
 
Materials and Methods 
 
Patients and bladder tissues 
Biopsies from normal urothelium, obtained from cystectomized bladders, were used as 
normal bladder tissues. A pathologist confirmed microscopically that these biopsies were  
tumor cell negative. Tumor tissues were obtained from 42 patients with UCC, of which 
36 were primary tumors. Patients were hospitalized at the Canisius Wilhelmina Hospital 
or the Radboud University Nijmegen Medical Center, The Netherlands. Tumors were 
removed by transurethral resection or radical cystectomy and histopathological 
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parameters were evaluated using the WHO criteria for grade (11) and TNM 
classification for stage (12). Tumor subtypes were as follows, stage: 12 Ta, 9 T1, 11 T2 
and 10 T3; grade: 5 GI, 17 GII and 20 GIII. Of all tumor biopsies obtained from the 42 
patients, the percentage of tumor cells was assessed by a pathologist prior to RNA 
isolation. All tissues were stored frozen at -80°C. The following bladder cancer cell lines 
were used: SW780, HTB-1, HTB-2 (RT4), HTB-4 (T24), HTB-9, RT112, SD and 253J. 
After transurethral resection, 14 of 21 patients with superficial disease (Ta/T1) were  
treated with adjuvant intravesical instillations. Ten of 21 patients with invasive disease 
(T2/T3) were treated with chemotherapy or radiotherapy after surgery. Patients were 
followed clinically from the moment of tumor tissue collection. The mean follow-up 
period was 70.6 months (range 2 - 183 months). The survival period and, if deceased, the 
cause of death was determined for all 42 patients. The time to first recurrence and tumor 
progression (Ta/T1 to T2 or higher) was only determined for the group of patients with 
superficial disease. 
 
RNA isolation and RT-PCR 
From all tissues, ten frozen 20 μM sections were disrupted in 1 ml Trizol (Life 
Technologies, Breda, The Netherlands) using a sterile pestle. Further steps followed the 
manufacturer's protocol. The percentage of tumor cells in the tumor tissues was 
investigated by hematoxylin and eosin staining of several 4 μM sections, taken at regular 
intervals between the 20 μM sections. Total RNA was only isolated from tumor biopsies 
containing >50% tumor cells, which in some cases was achieved by trimming the biopsy 
after staining of a test section. The RT-PCR protocol was as described previously in 
detail (13). 
 
Real-Time Quantitative PCR 
CDC91L1 and β-actin mRNA were measured in 1 μl of cDNA using the TaqMan® 
Assay-on-Demand™ Gene Expression Product and the Pre-Developed Assay Reagent, 
respectively, according to the manufacturers’ instructions (PE Applied Biosystems). In 
each sample mRNA expression of the housekeeping gene β-actin was measured to 
normalize CDC91L1 mRNA expression for sample-to-sample differences in RNA 
quality and reverse transcription efficiency. The formula 2−(Cycle threshold CDC91L1 – Cycle threshold 
β-actin)
 was used to calculate normalized CDC91L1 expression (9). 
 
Statistical analysis 
To detect a correlation between tumor parameters and normalized CDC91L1 expression, 
we compared median normalized CDC91L1 values between the four tumor stages (Ta, 
T1, T2, T3) and between the three differentiation grades (GI, GII, GIII). Differences 
were tested for statistical significance using the Kruskal-Wallis test. 
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A correlation of normalized CDC91L1 mRNA expression with time to first 
recurrence, tumor progression, overall, and disease-specific survival was evaluated using 
survival analyses. For all four clinical parameters, Kaplan-Meier curves were 
constructed for patients with a normalized CDC91L1 expression below and above the 
median value. The curves were compared with the log-rank test. 
The Statistical Package for Social Sciences (SPSS), release 12.0.1 (Nov, 2003), was 
used for analyses and statistical significance was indicated when the p-value was less 
than 0.05. 
 
Results 
 
Expression of CDC91L1 mRNA was quantified in 8 bladder cancer cell lines, 14 normal 
bladder tissues and 42 bladder tumor tissues (Figure 1). The housekeeping gene β-actin 
was used as normalization control. Only one (2.4%) of the tumor tissues showed higher 
CDC91L1 mRNA expression than normal urothelium. Also, the eight bladder cancer cell 
lines showed CDC91L1 mRNA expression levels comparable to that of normal 
urothelium, with  RT112 showing the highest and SW780 the lowest CDC91L1 mRNA 
expression.  
 
Figure 1. Normalized CDC91L1 
mRNA expression in bladder 
cancer cell lines, normal bladder 
tissues and bladder cancer tissues. 
Median normalized CDC91L1 
mRNA expression values (range 
between brackets) for cell lines, 
normal tissues and cancer tissues 
were: 0.15 (0.04-0.48); 0.30 (0.10-
1.65); 0.19 (0.05-1.72). 
Normalized CDC91L1 mRNA 
expression was calculated using 
the formula 2−(Cycle threshold CDC91L1 – 
Cycle threshold β-actin). 
 
Next, we investigated whether normalized CDC91L1 mRNA expression levels 
couidentify muscle-invasive and/or high grade UCCs (Figure 2). The median normalized 
CDC91L1 mRNA expression values of stage Ta, T1, T2, and T3 tumors were 0.22, 0.19, 
0.16, and 0.33, respectively (Figure 2A). Grade I, grade II, and grade III tumors had 
mediannormalized CDC91L1 expression values of 0.26, 0.18, and 0.33, respectively 
(Figure 2B). The Kruskal-Wallis test indicated no differences in CDC91L1 mRNA 
expression for stage (p = 0.962) nor grade (p = 0.557). 
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Figure 2. Distribution of normalized CDC91L1 mRNA expression according to bladder tumor 
stage (A) and grade (B). Median normalized CDC91L1 mRNA expression values (range between 
brackets) for tumor stages and grades were: Ta, 0.22 (0.08-0.84); T1, 0.19 (0.07-0.55); T2, 0.16 
(0.05-1.72); T3, 0.33 (0.05-0.58); GI, 0.26 (0.12-0.33); GII, 0.18 (0.07-0.69) and GIII, 0.33 (0.05-
1.72). Normalized CDC91L1 mRNA expression was calculated using the equation 2−(Cycle threshold 
CDC91L1 – Cycle threshold β-actin). 
 
Subsequently, a correlation between CDC91L1 expression and clinical follow-up 
parameters was investigated using survival analysis. Clinical data concerning both 
recurrence and tumor progression, overall survival and disease specific survival were 
missing for 1, 3, and 6 patients, respectively. Kaplan-Meier curves were constructed for 
patients with a CDC91L1 expression below and above the median value, and compared 
with the log rank test. Of the remaining 20 patients with superficial UCC, 9 and 6 
patients had tumor recurrences within and after one year, respectively. Two patients died 
recurrence-free (after 52 and 64 months) and 3 patients remained recurrence-free until 
the end of the follow-up period. The CDC91L1 mRNA expression level did not predict 
early tumor recurrence (log rank p-value = 0.1629). Five patients with superficial disease 
showed tumor progression, but CDCD91L1 expression levels did not identify these 
patients (log rank p-value = 0.9307). Finally, CDC91L1 mRNA copy numbers did not 
predict overall or disease-specific survival (log rank p-values 0.9193 and 0.4710, 
respectively). 
 
Discussion 
 
In response to the recent discovery of CDC91L1 as a new oncogene in bladder cancer, 
we further evaluated its mRNA expression in bladder cancer cell lines, normal 
urothelium and bladder cancer tissues. In addition, we studied its possible prognostic 
value within the cohort of bladder tumors. 
For calculation of normalized CDC91L1 expression, we initially used the equation 
presented in the article by Guo et al. (8). Similar to Guo et al., who detected CDC91L1 
overexpression in 22 of 61 (36%) tumors compared to normal tissues, we observed  
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CDC91L1 overexpression in 9 of 42 (21.4%) tumors. Also, in agreement, SW780 had 
the highest CDC91L1 expression of the cell lines tested. However, from the corrigendum 
of their original article it appeared that the equation was incorrect (9). After using the 
corrected equation, we observed CDC91L1 overexpression in only 1 of 42 (2.4%) 
tumors. Furthermore, cell line SW780 now displayed the lowest  CDC91L1 mRNA 
expression. 
Additionally, the discrepancy of CDC91L1 overexpression in tumors compared with 
normal tissues between our results and those of Guo et al., may also be attributable to a 
different selection of bladder cancer tissues and normal urothelium or the distribution of 
tumor subtypes. Guo et al. do not mention these characteristics. The tumor samples 
selected for our study contained at least 50% tumor cells. Furthermore, the normal 
bladder tissues did not contain tumor cells and none expressed the reverse transcriptase 
subunit of the highly tumor specific marker telomerase, whereas all tumors did (14) (data 
not shown). Also, all different tumor subtypes were represented in our study: half of the 
tumors were superficial and the other half muscle invasive. 
Normally, one would expect that the expression of an oncogene increases as the 
tumor becomes more aggressive and rises above the expression level in normal tissue. 
Since we observed overexpression of CDC91L1 mRNA in only one tumor compared to 
normal tissues, it is therefore not surprising that no correlation between CDC91L1 
expression and increasing tumor stage or grade was found. Also, CDC91L1 mRNA 
expression was not predictive of early tumor recurrence, tumor progression and overall 
or disease-specific survival. It may be possible that not mRNA expression but CDC91L1 
protein expression is upregulated and provides better prognostic information. This 
remains to be investigated. 
The results from our study indicate that CDC91L1 mRNA is not overexpressed in 
bladder cancer and has no prognostic value in this disease. Further experiments should 
clarify the discrepancy in CDC91L1 mRNA overexpression between our study and that 
of Guo et al. CDC91L1 protein expression in bladder tumors and its possible prognostic 
value remain to be investigated and may prove more informative. This may also answer 
the question whether CDC91L1 will be an interesting therapeutic target in patients with 
bladder cancer. 
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Abstract 
 
The serine threonine kinase 15 (STK15) plays an important role in tumorigenesis and 
tumor progression. The T91A polymorphism in this gene is associated with aneuploidy 
and with an advanced disease stage in patients with colorectal and esophageal squamous 
cell carcinoma, respectively. We investigated the prognostic role of the STK15 T91A 
polymorphism and of STK15 mRNA expression in patients with urothelial cell 
carcinoma (UCC). The STK15 genotype with respect to the T91A polymorphism was 
assessed by restriction fragment length polymorphism in 135 patients. STK15 mRNA 
expression was measured in tumor tissues of 103 patients, using real-time quantitative 
PCR. The T91A polymorphism lacked any prognostic information in our patient cohort. 
Interestingly though, STK15 mRNA expression was increased in invasive and high-
grade tumors (p-values are 0.009 and 0.0001, respectively). Additionally, patients with 
superficial UCC (n=82) who had a tumor recurrence in the first year after surgery 
displayed elevated STK15 mRNA expression levels in their tumors (Wilcoxon p-value = 
0.009). Kaplan-Meier survival analysis revealed an increased risk of tumor progression 
for patients with Ta tumors (n=62) and STK15 expression above the median (log-rank p-
value = 0.04). Furthermore, a decreased overall (log-rank p = 0.006) and UCC-specific 
survival (log-rank p = 0.001) was shown for patients with elevated STK15 mRNA 
levels. Thus, patients with UCC and elevated levels of STK15 mRNA generally show a 
more adverse disease course than patients with low levels. This may help in identifying 
patients who need more aggressive treatment. It also pinpoints STK15 as a possible 
interesting therapeutic target in UCC. 
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Introduction 
 
The tight control of all steps leading to cell division helps to prevent neoplastic cell 
transformation. An important step in this process is the proper segregation of 
chromosomes to daughter cells. Defects in this mechanism can lead to chromosomal 
instability, a process frequently seen in human cancer cells (1). A key regulator of 
chromosomal segregation is the centrosome, which controls the formation of the mitotic 
spindle and which is the major microtubule-organizing center of the cell (2). In cancer 
cells, centrosome abnormalities and chromosome instability frequently accompany each 
other (3, 4). Therefore, genes involved in centrosome function and stabilization play an 
important role during cell division. One of these genes is the serine/threonine protein 
kinase STK15. 
 STK15 belongs to the Aurora/Ipl1 family of kinases, which are important regulators 
of chromosome segregation and mitosis (5). The gene resides on chromosomal arm 
20q13, a region that is frequently amplified in human cancer. Gene amplification and 
overexpression of STK15 leads to an alteration in centrosome number and aneuploidy in 
tumor cells (6). Several studies have linked STK15 overexpression or gene amplification 
with an adverse disease course in different types of cancer (7-11). 
 Recently, more insight into the molecular mechanism underlying centrosome 
amplification and induction of aneuploidy by STK15 was provided (12). A 
polymorphism in the STK15 coding sequence at position 91 results in the replacement of 
a Thymine by an Adenine. The variant 91A allele was preferentially amplified in 
heterozygous patients with colon cancer and the presence of this allele was associated 
with increased aneuploidy in the tumors (12).  Furthermore, the protein encoded by the 
91A allele, in which a phenylalanine is replaced by an isoleucine, conferred a growth 
advantage to transformed cells compared to the wild-type 91T allele (12). Thus, the 
STK15 T91A polymorphism may not only induce chromosome instability, but may also 
affect tumor growth. An association between this polymorphism and the diagnosis of a 
more advanced disease stage in patients with esophageal squamous cell carcinoma was 
shown recently (13). This indicates a possible prognostic role for the T91A 
polymorphism. 
 A recent study showed that STK15 can induce chromosomal instability in bladder 
cancer cells (14). The latter, in combination with the important role of the STK15 T91A 
polymorphism in inducing chromosomal instability and its association with an advanced 
stage of human cancer, led us to investigate the prognostic role of the STK15 T91A 
polymorphism in patients with urothelial cell carcinoma (UCC). In addition, we 
evaluated the prognostic utility of STK15 mRNA expression in this disease. 
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Materials and Methods 
 
Patients and Samples 
In total, 218 patients with UCC were selected for the study. From 153 patients, tumors 
were obtained after transurethral resection (n=132) or cystectomy (n=21) and 
histopathological parameters were evaluated using the WHO criteria for grade (15) and 
TNM classification for stage (16). These tumors were obtained from the Department of 
Urology of the University Hospital in Uppsala (Sweden), the Department of Urology of 
the Charles University in Prague (Czech Republic) and from the Department of Urology 
of the Radboud University Nijmegen Medical Centre in Nijmegen (The Netherlands). 
The tissues were stored at -80°C. From the other 65 patients, bladder washings had 
previously been collected by the Department of Urology of the Canisius Wilhelmina 
Hospital in Nijmegen. DNA isolated from these bladder washings was kindly provided 
to us. All material has been collected with approval of the local ethical committees. 
 
DNA/RNA Isolation and cDNA Synthesis 
Of each tumor biopsy, the percentage of tumor cells was assessed. To this end, two 5 μM 
cryosections, flanking 10x 20μM sections for RNA isolation, were stained with 
haematoxylin and eosin. Subsequently, RNA was isolated from biopsies containing ≥ 
50% tumor cells. Initially, tumor sections were pestled in a small amount of TRIZol® 
Reagent (Invitrogen) using sterile pestles (Kimble Kontes). Subsequent RNA and DNA 
isolation were performed using TRIZol according to the manufacturer's protocol. The 
isolated DNA was stored at -20°C. The isolated RNA was further purified using the 
RNeasy Mini Kit (Qiagen), during which remaining DNA was removed with the RNase-
Free DNase set (Qiagen). RNA yield and purity were checked on a spectrophotometer at 
OD260 (Gene Quant pro, Amersham Biosciences). Reactions for cDNA synthesis 
contained ~1 μg RNA, 1x PCR buffer (Perkin Elmer (PE)), 5.5 mM MgCl2, 0.5 mM 
dNTPs, 2.5 μM Random Hexamers (Applied Biosystems (AB)), 25 units MultiScribe 
(AB), 8 units RNase Inhibitor (AB), in a 20 μL volume. Before cDNA synthesis RNA 
was denatured at 95°C for 5 min. after which the samples were put on ice immediately. 
The protocol for cDNA synthesis was 10 min. 25°C, 30 min. 48°C and 5 min 95°C. The 
cDNA was stored at -20°C. 
 
Restriction Fragment Length Polymorphism 
A PCR reaction for STK15 amplification contained ~25 to 50 ng DNA, 1x PCR buffer 
(PE), 2.5 mM MgCl2, 50 μM dNTPs, 1 unit AmpliTaq Gold™ (AB), and 400 nM of 
each primer in a 50 μl volume. The primers for amplification of STK15 were: 5'-
TTTTGCTATACTAGAG-AACAAACTTT-GTGA-3' (forward) and 5'-
GCTAAGGCTCCAAACAATAAGTGC-3' (reverse). The PCR protocol was 10 min. 
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95°C, 40x (30 sec. 95°C, 30 sec 60°C, 45 sec. 72°C) and 10 min. 72°C. Afterwards, 20 
μl of the 470-basepair PCR product was digested with 10 units of ApoI (New England 
Biolabs (NEB)) in a 25 μl volume containing 1x NEBuffer 3 (NEB) and 1x BSA (NEB) 
for 2 hours at 50°C. The three genotypes with respect to the T91A STK15 polymorphism 
yield different digestion patterns. T/T yields DNA fragments of 261, 178 and 32 
basepairs (bps), T/A yields fragments of 261, 178, 114, 64 and 32 bps and A/A yields 
fragments of 261, 114, 64 and 32 bps. 
 
Real-time Quantitative PCR 
Real-time Q-PCR detection of cyclophilin A (housekeeping gene for expression 
normalization) and STK15 was conducted in separate 25 μl PCR reactions, which each 
contained 1 μL cDNA and 1x TaqMan® Universal PCR Master Mix (No AmpErase® 
UNG, AB), with either 1x cyclophilin A TaqMan® Endogenous Control (containing 
primers and a VIC-Tamra Probe (AB)) for cyclophilin detection or 600 nM STK15 
primers and 200 nM STK15 probe for STK15 detection. Primer Express™ version 1.5 
software (AB) was used to develop primers and a probe for STK15 detection: 5'-
ATTTCAGGACCTGT-TAAGGCTACAG-3' (forward), 5'-GAGCCTGGCCACTAT-
TTACAGGTA-3' (reverse) and 5'-TET-CTGAGTCACGAGAACACGTTTTGGACC-
TCC-TAMRA-3’ (probe). The PCR protocol for both genes was 10 min. 95°C followed 
by 40x (15 sec. 95°C, 1 min. 60°C). Real-time PCR quantification of cDNA was 
performed using the ABI PRISM® 7700 Sequence Detection System (AB). The data 
were analyzed with Sequence Detector version 1.9.1 software (AB). Samples with a 
cyclophilin A cycle threshold (Ct) above 34 were excluded, because this indicated poor 
cDNA quality. STK15 mRNA expression was normalized using the formula: 2 - (Ct STK15- 
Ct Cyclophilin A) (17).  
 
Statistical Analysis 
Deviation of the STK15 T91A allele frequency in the patient cohort from those expected 
under Hardy-Weinberg equilibrium was tested for statistical significance using the Chi-
Square (χ
2
) test. For the analysis of a relationship between the STK15 genotype (3 
categories) and primary UCC stage (3 categories) or grade (3 categories), cross 
tabulations were generated and differences were tested for statistical significance using 
the Chi-Square (χ
2
) test. Kaplan-Meier survival analysis was used to investigate a 
relationship between the STK15 genotype and the clinical parameters recurrence and 
progression (defined as the transition from Ta or T1 to T2 or higher, or UCC-specific 
death in patients diagnosed with superficial cancer) in the group of patients with 
superficial UCC, and between the STK15 genotype and the clinical parameter survival in 
patients with superficial or invasive (≥T2) UCC. Kaplan-Meier survival curves were 
constructed for each of the three STK15 genotypes and compared with the log-rank test. 
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 For the analysis of a relationship between STK15 mRNA expression and tumor stage 
or tumor grade the Kruskal-Wallis test was used. Kaplan-Meier survival analysis was 
used to investigate the relationship between STK15 expression and the recurrence-free 
period. To detect differences in expression between patients with superficial UCC with a 
recurrence within 1 year or those who remained recurrence-free for at least 1 year, the 
Mann-Whitney U test was applied. A relationship between STK15 expression and the 
time to progression and overall or UCC-specific survival was investigated by Kaplan-
Meier survival analysis. For these analyses, curves were constructed for patients with 
STK15 expression above or below the median, which were compared with the log-rank 
test. 
 Statistical significance was indicated when the p-value was < 0.05. For the analyses, 
the Statistical Package for Social Sciences (SPSS) version 12.0.1 software was used. 
 
Results 
 
STK15 Genotype 
The STK15 T91A polymorphism was assessed for a total of 135 patients. This group of 
patients consisted of 105 men and 29 women, with an average age at time of diagnosis of 
67 years (range 36 - 90). The distribution of the T/T, T/A and A/A STK15 genotype 
among the 135 patients was 73 (54%), 55 (41%) and 7 (5%), respectively. The χ
2
 test 
indicated no significant deviation from the expected allele frequencies under Hardy-
Weinberg equilibrium (χ
2 
= 0.68, p = 0.41). 
 We first investigated whether one of the three different STK15 genotypes was 
associated with a more advanced disease stage at the time of diagnosis. The pathologic 
data with regard to tumor stage and grade were available for 132 patients. The  
 
 
Table 1. Distribution of the different tumor stages and grades among the three STK15 genotypes 
with respect to the T91A polymorphism, in patients with UCC1 
                 STK15 Genotype 
      Total No. (%)    T/T (%)   T/A (%)   A/A (%) 
Patients    132     72 (54.5)   53 (40.2)   7 (5.3) 
Stage2   Ta   73      40 (54.8)   28 (38.4)   5 (6.8) 
    T1   34      19 (55.9)   13 (38.2)   2 (5.9) 
    T2-3  25      13 (52.0)   12 (48.0)   0 (0) 
Grade3 1   18      10 (55.6)   8 (44.4)   0 (0) 
    2   65      35 (53.8)   24 (36.9)   6 (9.2) 
    3   49      27 (55.1)   21 (42.9)   1 (2.0) 
1UCC = Urothelial Cell Carcinoma. 
2The χ2 test did not reveal an association between STK15 genotype and primary tumor stage, p-value = 0.70. 
3
The χ
2
 test did not reveal an association between STK15 genotype and primary tumor grade, p-value is 0.38. 
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distribution of the different tumor stages and grades among the three STK15 genotypes 
with respect to the T91A polymorphism is presented in Table 1. The χ
2
 test did not 
reveal a statistically significant relationship between a specific STK15 genotype and 
increased primary tumor stage (p = 0.70) or grade (p = 0.38). 
 Subsequently, a relationship between the STK15 genotype and the clinical parameters 
was investigated. Clinical data with respect to tumor recurrence and tumor progression 
were available for 102 patients with superficial UCC. Kaplan-Meier survival analysis did 
not reveal a relationship between STK15 genotype and tumor recurrence (log-rank p-
value = 0.41) or the time to progression (log-rank p-value = 0.8). Data with respect to 
overall and UCC-specific survival were present for 113 and 91 patients, respectively. 
Comparison of the Kaplan-Meier survival curves did not show a statistical relationship 
between the STK15 genotype and overall and UCC-specific survival (log-rank p-values 
are 0.36 and 0.58, respectively). 
 
STK15 Expression 
After selection of tumor biopsies with a tumor cell percentage above 50% and a 
subsequent cyclophilin Ct below 34 after cDNA quality evaluation, 103 tumors remained 
(23 had a tumor cell percentage < 50 and 27 had a cyclophilin Ct > 34). The patient 
group consisted of 80 men and 23 women, with a mean age of 67 years (range 42 - 90). 
Eighty-two tumors were superficial (62 Ta, 20 T1), of which 70 were primary. Twenty-
one tumors were invasive (≥T2), of which 20 were primary. Of the patients with 
superficial tumors, 22 received adjuvant treatment (15x Bacillus Calmette-Guérin, 6x 
Mitomycin, 1x  Epirubicine) after transurethral tumor resection. All patients with  
 
 
Figure 1. Distribution of STK15 
expression across tumor stage and grade 
in patients with UCC. The boxes 
represent the interquartile range. Open 
triangles represent outliers. The median 
STK15 expression levels (thick black 
horizontal bars) for the different tumor 
stages and grades are (range in 
parenthesis): Ta, 0.55 (0.07-7.41); T1, 
0.68 (0.12-7.06); T2, 1.15 (0.25-6.87); 
G1, 0.52 (0.08-2.25); G2, 0.53 (0.07-
7.41); G3, 1.51 (0.25-6.92). 
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invasive cancer were treated with cystectomy. 
First, a relationship between STK15 mRNA expression and pathological tumor stage 
and grade was investigated. STK15 expression was normalized with cyclophilin A, to 
correct for differences in cDNA input for each sample. The STK15 expression levels for 
Ta, T1 and T2 or higher, as well as those for G1, G2 and G3 tumors were compared 
using the Kruskal-Wallis test. Significantly elevated STK15 expression levels were 
noted in invasive (p = 0.009) and high-grade tumors (p = 0.0001; Fig. 1). 
Next, a relationship between STK15 expression and the recurrence-free period was 
investigated for patients with superficial tumors (Ta and T1, n = 82). Kaplan-Meier 
curves were constructed for patients with STK15 expression below or above the median. 
There was no statistical difference between these two groups with respect to the 
recurrence-free period (log-rank p-value = 0.21). However, when we compared the 
STK15 mRNA expression level between patients who had recurrences within 1 year and 
those who remained recurrence-free for at least 1 year, statistical significant differences 
were observed (p = 0.009; Fig. 2). 
We then analyzed the prognostic value of STK15 expression with regard to the time to 
tumor progression (as defined above) in patients with Ta and T1 tumors (n = 82). 
Patients were divided into a group with STK15 expression below and one with 
expression above the median. Kaplan-Meier curves were constructed for these groups, 
which were compared with the log-rank test. This did not reveal a statistical significant 
relationship (log-rank = 0.07). On the other hand, when we only analyzed patients with  
 
 
Figure 2. Distribution of STK15 mRNA 
expression in patients with superficial 
UCC (n=82) and recurrences within one 
year (n=27) or recurrence-free for at least 
one year (n=55). The boxes represent the 
interquartile range. Open triangles 
represent outliers. The median expression 
levels (thick horizontal bar) for the groups 
without or with recurrences within one 
year are (range in parenthesis), 
respectively, 0.51 (0.07-7.41) and 0.93 
(0.21-7.06). 
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Figure 3. Kaplan-Meier survival 
analysis of the relationship between 
STK15 expression and the time to 
tumor progression in 62 patients 
with superficial Ta tumors. Patients 
were divided into those having 
STK15 expression above (solid 
line) and below (dashed line) the 
median level. 
 
 
 
 
 
 
 
Ta tumors (n = 62), high STK15 expression showed a relationship with early tumor 
progression (log-rank = 0.04; Fig. 3). Of the Ta patients with STK15 expression below 
or above the median, 1 and 6 patients developed progression, respectively. 
Finally, a relationship between STK15 expression and overall or UCC-specific 
survival was investigated for patients with both superficial and invasive UCC (Fig. 4). 
Clinical data regarding overall and UCC-specific survival was available for 82 and 55 
patients, respectively. For both analyses, Kaplan-Meier curves were constructed for 
patients with an STK15 expression level below and above the median. High STK15 
expression was related to a decreased overall survival (log-rank = 0.006; Fig. 4A) and 
decreased UCC-specific survival (log-rank = 0.001; Fig. 4B). In the case of UCC-
specific survival, 1 and 12 patients died of UCC in the group with low and high STK15 
expression, respectively. 
 
Discussion 
 
The discovery of STK15 as a critical factor in the induction of genetic instability in 
tumor cells has triggered research concerning its role in human cancer (7-9, 11). In 
bladder cancer, STK15 gene amplification and protein overexpression were associated 
with the induction of aneuploidy and with an adverse disease course (10, 14). A recent 
study revealed an important role for the STK15 T91A polymorphism in the induction of 
aneuploidy in tumor cells (12). We investigated the possible prognostic role of both the 
functional STK15 T91A polymorphism and of STK15 mRNA expression in patients with 
UCC of the bladder. 
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Figure 4. Kaplan-Meier survival analysis of the relationship between STK15 expression and 
overall (A) or UCC-specific (B) survival in patients with superficial and invasive UCC. For both 
overall survival (n=82) and UCC-specific survival (n=55) patients were divided into those having 
STK15 expression above (solid lines) and below (dashed lines) the median level. Increased STK15 
expression was associated with decreased overall survival (log-rank p-value =0.006) and decreased 
UCC-specific survival (log-rank p-value = 0.001). 
 
The T91A polymorphism in the STK15 coding region was initially presented as a 
low-penetrance cancer susceptibility allele (12). This was confirmed in a large study 
evaluating the effect of the polymorphism on the risk of developing different types of 
human cancer (18). Another study also associated the variant STK15 A allele with an 
increased tumor stage and grade at the time of cancer diagnosis in patients with 
esophageal squamous cell carcinoma (13). In patients with bladder cancer, however, we 
did not find a relationship between the STK15 T91A polymorphism and a higher primary 
tumor stage or grade. Additionally, the polymorphism appears to lack any prognostic 
value in this disease. The difference in the results between our study and that of Miao et 
al. may be attributable to the distribution of the STK15 T91A polymorphism in our and 
their patient cohort (13). The number of patients homozygous for the STK15 A allele is 
much higher in their patient cohort (47%) than in ours (5%), representing the difference 
in the distribution of the STK15 T91A polymorphism among the Chinese and the 
Caucasian population (18). Due to the high percentage of patients with the STK15 91A 
variant, its adverse effect may have been more pronounced in the study by Miao et al. It 
appears that the STK15 T91A polymorphism has no prognostic role in patients with 
bladder cancer among Caucasians, although this has to be confirmed in larger studies. 
 The study of STK15 protein expression in patients with bladder cancer has yielded 
better results with respect to disease prognosis. Sen et al. showed a relationship between 
elevated STK15 protein expression and an increased rate of bladder tumor metastasis, 
decreased metastasis-free and overall survival (10). Also, high STK15 mRNA 
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expression was detected in some invasive T3 bladder tumors (14). We further confirmed 
and showed additional prognostic information for STK15 in patients with bladder 
cancer. STK15 mRNA expression was elevated in invasive and high-grade tumors. 
Additionally, patients with superficial tumors and recurrences within one year displayed 
increased STK15 mRNA levels compared to patients who remained recurrence-free for 
at least one year. Also in patients with Ta tumors, elevated STK15 mRNA levels suggest 
an increased risk of developing tumor progression. Finally, decreased overall and UCC-
specific survival was detected for patients with high STK15 mRNA expression. The 
findings indicate that, in our cohort, patients whose tumors have elevated STK15 mRNA 
expression generally show a more adverse disease course compared to patients with low 
STK15 mRNA levels. 
 Our results are in line with those obtained by Sen et al., who showed upregulation of 
STK15 protein expression in invasive and high-grade bladder tumors (10). The findings 
of both studies suggest a more adverse disease course for patients with elevated levels of 
STK15 mRNA or protein, and may indicate the need for more aggressive treatment of 
such patients to control the disease. Furthermore, several studies have shown successful 
treatment of bladder cancer cells by targeting upregulated genes (19-24). Therefore, 
STK15 could possibly constitute an interesting therapeutic target in patients with UCC. 
Future confirmation of the prognostic role of STK15 in UCC is necessary and may result 
in experiments concerning the treatment of bladder cancer cells by attacking STK15. 
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Abstract 
 
Accurate prediction of tumor recurrence in patients with superficial urothelial cell 
carcinoma (UCC) might result in a significant reduction of invasive follow-up 
cystoscopies. A recent study identified a panel of 26 genes from a large cDNA 
microarray analysis of bladder tumors that discriminated between early- and late-
recurring patients with superficial Ta tumors (Dyrskjøt L et al. Nat Genet 2003;33:90-6). 
We aimed to validate this panel of genes in 44 primary Ta UCCs (23 and 21 tumors from 
patients with short or prolonged recurrence-free periods, respectively), by real-time 
quantitative PCR. Statistical analysis showed marginal significant different mRNA 
expression levels between the two patient groups. To evaluate a supplementary effect of 
genes for the identification of patients with short or prolonged recurrence-free intervals, 
forward logistic regression analysis was applied. This revealed that a combination of the 
expression profiles of the genes HNRPK, LTB4DH and ANP32B resulted in the best 
performance, although the combination only marginally increased the predictive value of 
HNRPK alone. Comparing the receiver-operating-characteristic curves for HNRPK 
expression among patients with short or prolonged recurrence-free periods, revealed an 
area under the curve of 0.696 (95% CI, 0.537-0.855). Using the median HNRPK 
expression level as cut-off, a sensitivity of 69.6% and a specificity of 71.4% were 
obtained for the identification of patients with short or prolonged recurrence-free 
periods, respectively. In conclusion, we were not able to confirm the microarray gene 
expression pattern of the 26 genes shown by Dyrskjøt et al. The discovery of accurate 
recurrence predictive markers, therefore, remains a challenge. 
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Introduction 
 
Urothelial cell carcinoma (UCC) comprises up to 95% of human bladder cancer. It 
originates in the urothelium, the layer of cells lining the inner bladder wall. The larger 
part of patients with UCC is diagnosed with superficial tumors, pTNM stages Ta and T1, 
of which the depth of organ invasion is limited to the stromal mucosa. These tumors can 
be removed relatively easy by transurethral resection. Unfortunately, approximately 70% 
of these patients experience recurrences after tumor removal and some will show 
progression towards muscle invasive disease. This necessitates frequent examination of 
the bladder by cystoscopy, which is invasive and represents a burden to the patient. The 
monitoring of these patients also includes those who will remain recurrence-free for 
several years or even for the rest of their lives. This generates a substantial number of 
unnecessary cystoscopies, which may be prevented by accurate prediction of tumor 
recurrence (or non-recurrence) in patients with superficial UCC. 
 The current standards for the estimation of the risk of recurrence are tumor grade, 
size and multiplicity.1-3 Although these factors are relatively accurate in the group of 
patients with superficial UCC, improvement in the prediction of tumor recurrence in 
individuals is needed.4-6 Many studies have investigated the prognostic potential of 
molecular markers to supplement or even replace the current standards. Several markers 
show a relationship with early tumor recurrence in patients with superficial UCC.
7-12
 
Also, molecular grading of UCC showed improved predictive potential compared to 
classical pathological parameters.
13
 Despite these advances, no molecular marker is 
integrated in clinical prognostics yet. 
 In the ongoing search for recurrence-predictive markers, several studies have 
attempted to molecularly classify bladder tumors by cDNA microarray analysis.
14-18
 One 
of these studies identified a panel of 26 genes, which distinguished between early-
recurring and non-recurring superficial Ta tumors in a cohort of 31 patients.
16
 This set of 
recurrence-predictive genes, if confirmed, may help in reducing the number of follow-up 
cystoscopies in a subgroup of patients. 
 The aim of this study was to validate the recurrence-predictive power of the 26 genes 
discovered by Dyrskjøt et al. Using real-time quantitative PCR (Q-PCR); we 
investigated mRNA expression of the genes in an independent panel of 44 primary Ta 
UCCs from patients with short or prolonged recurrence-free periods. Statistical analysis 
was performed to assess differential expression of each gene between the two patient 
groups. The recurrence-predictive power of the genes was further investigated by 
forward logistic regression analysis and quantified by calculating the area under the 
curve (AUC) using receiver-operating-characteristic (ROC) analysis. 
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Materials and Methods 
 
Tumor Specimens 
In total, 80 primary Ta UCCs were selected from bladder tumor collections of the 
bladder tumor biobank of the Department of Urology of the University Hospital in 
Uppsala (Sweden), the Department of Urology of the Charles University in Prague 
(Czech Republic) and from the Department of Urology of the Radboud University 
Nijmegen Medical Center in Nijmegen (The Netherlands). The tumors have been 
removed by transurethral resection and histopathological parameters were evaluated 
using the WHO criteria for grade
19
 and TNM classification for stage.
20
 All tissues were 
stored at -80°C. The tumors have been collected with approval of the local ethical 
committees. 
We selected tumors from patients who experienced recurrences within two years (R-
group) or who remained recurrence-free for at least four years (NR-group). All patients 
received their first follow-up examination three months after primary surgery. These and 
following bladder examinations were performed by means of cystoscopy and urine 
cytology. 
 
RNA Isolation and cDNA Synthesis 
Prior to RNA isolation, the percentage of tumor cells in each biopsy was assessed. To 
this end, two 5 μM cryosections, flanking 10x 20μM sections for RNA isolation, were 
stained with haematoxylin and eosin. Only biopsies containing ≥ 50% tumor cells were 
selected for further analysis. Initially, tumor sections were pestled in a small amount of 
TRIZol
®
 Reagent (Invitrogen) using sterile pestles (Kimble Kontes). Subsequent RNA 
isolation was performed using TRIZol according to the manufacturer's instructions. The 
isolated RNA was further purified using the RNeasy Mini Kit (Qiagen), during which 
remaining DNA was removed with the RNase-Free DNase set (Qiagen). RNA yield and 
purity were checked on a spectrophotometer (Gene Quant pro, Amersham Biosciences) 
at OD260. Reactions for cDNA synthesis contained: ~1 μg RNA, 1x PCR buffer (Perkin 
Elmer), 5.5 mM MgCl2, 0.5 mM dNTPs, 2.5 μM Random Hexamers (Applied 
Biosystems (AB)), 25 units Multiscribe (AB), 8 units RNase Inhibitor (AB), in a 20 μL 
volume. Before cDNA synthesis RNA was denatured at 95°C for 5 min. after which the 
samples were put on ice immediately. The protocol for cDNA synthesis was as follows: 
10 min. 25°C, 30 min. 48°C and 5 min 95°C. The cDNA was stored at -20°C. 
 
Real-time Quantitative PCR 
The mRNA expression of 24 of the 26 target genes was analyzed on a 384-well format 
TaqMan® Low Density Array (LDA) using the 7900HT Fast Real-Time PCR System 
(AB). The LDA contained pre-spotted primers and probes for the detection of the 
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internal RNA quality control 18S ribosomal RNA, the housekeeping gene cyclophilin A 
(for expression normalization
21
) and 24 target genes. The PCR reaction on the LDA was 
performed in a 2 µL volume containing 2-4 ng cDNA and 1x TaqMan® Universal PCR 
Master Mix. The mRNA expression of the other 2 target genes (Eif3s5 and RBMX) was 
measured separately using the ABI PRISM® 7700 Sequence Detection System. Their 
PCR reactions contained 1 µL cDNA, 1x TaqMan® Gene Expression Assay (containing 
primers and probe (AB)), and 1x TaqMan® Universal PCR Master Mix (No 
AmpErase® UNG (AB)), in a 25 µL volume. An overview of the TaqMan® Gene 
Expression Assays used for mRNA expression analysis is given in Table 1. The PCR 
protocol for both the LDA and the separate genes was: 10 min. 95°C and 40x(15 sec. 
95°C, 1 min. 60°C). Generally, the PCR assays detect the part of the gene that was also 
detected by the cDNA microarray used by Dyrskjøt et al. The data for the LDA and the 
data for the two separate target genes were analyzed using the Sequence Detection 
System version 2.1 and Sequence Detector version 1.9.1. software, respectively. Only 
samples with an 18S ribosomal RNA Cycle Threshold (Ct) of < 20 were used for further 
analysis, because this indicated good cDNA quality. Target gene expression was 
normalized with cyclophilin expression using the formula 2 
- (Ct Target- Ct Cyclophilin A)
.
22
 
 
Heatmap Construction 
Gene expression data were uploaded into Cluster version 2.11.23 Genes were log-
transformed,  median centered and normalized, after which the gene weights were 
calculated. Treeview was used to visualize the gene expression data.
23
 
 
Statistical Analysis 
Differences in mRNA expression between the two different patient groups (non-
recurrent (NR) and recurrent (R)) were analyzed using the Wilcoxon test, with a p-value 
< 0.05 indicating statistical significance. The Bonferroni correction (p-value = 
0.05/number of tests) was applied to correct for multiple testing. To investigate whether 
gene expression profiles supplement each other and increase the predictive power for 
recurrence (in terms of sensitivity and specificity), forward logistic regression analysis 
was applied. A probability level of 0.52, obtained by dividing the number of patients in 
the largest group (n=23) by the total number of patients (n=44), was used as cut-off point 
to classify NR (<0.52) and R (>0.52) patients. Receiver-operating-characteristic (ROC) 
curves were created to indicate the performance of the genes with respect to the 
identification of patients with short or prolonged recurrence-free periods. Specificity and 
sensitivity refer to the identification of patients from the NR- and R-group, respectively. 
Genes were considered to have discriminative ability if the 95% confidence interval 
(95% CI) for the area under the curve (AUC) did not include 0.5.  
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Table 1: Overview of the genes measured by real-time quantitative PCR 
Gene              NCBI 
Symbol  Gene Full Name       RefSeq    Assay ID (AB) 
C1orf16  chromosome 1 open reading frame 16  NM_014837  Hs00208049_m1 
FOSB   FBJ murine osteosarcoma viral    NM_006732  Hs00171851_m1 
    oncogene homolog B 
DAXX   death-associated protein 6     NM_001350  Hs00154692_m1 
KIAA0196  KIAA0196         NM_014846  Hs00208146_m1 
ADRM1  adhesion regulating molecule 1   NM_007002  Hs00199645_m1 
COL4A6  collagen, type IV, alpha 6     NM_001847  Hs00361494_m1 
HOXC6  homeo box C6        NM_004503  Hs00171690_m1 
HTRA1  HtrA serine peptidase 1     NM_002775  Hs00170197_m1 
MFGE8  milk fat globule-EGF factor 8 protein  NM_005928  Hs00170712_m1 
SKIP   skeletal muscle and kidney enriched  NM_016532  Hs00213017_m1 
    inositol phosphatase 
CYR61  cysteine-rich, angiogenic inducer, 61  NM_001554  Hs00155479_m1 
Eif3s5   eukaryotic translation initiation   NM_003754  Hs01629178_s1 
    factor 3, subunit 5 epsilon, 47kDa 
LAMA3  laminin, alpha 3       NM_000227  Hs00165042_m1 
ANP32B  acidic (leucine-rich) nuclear phospho-  NM_006401  Hs00742713_s1 
    protein 32 family, member B 
PTPRN2  protein tyrosine phosphatase,    NM_002847  Hs00243067_m1 
    receptor type, N polypeptide 2 
MAPKAP1 mitogen-activated protein kinase   NM_024117  Hs00225549_m1 
    associated protein 1 
HNRPK  heterogeneous nuclear ribonucleo-   NM_002140  Hs00829140_s1 
    protein K 
D4S234E  DNA segment on chromosome 4   NM_014392  Hs00205189_m1 
    (unique) 234 expressed sequence 
AMFR   autocrine motility factor receptor   NM_001144  Hs00181609_m1 
LTB4DH  leukotriene B4 12-hydroxydehydro-  NM_012212  Hs00400932_m1 
    genase 
RHOQ   ras homolog gene family, member Q  NM_012249  Hs00817629_g1 
RBMX   RNA binding motif protein, X-linked  NM_002139  Hs00953944_g1 
GTF2E2  general transcription factor IIE,   NM_002095  Hs00157831_m1 
    polypeptide 2, beta 34kDa 
MTHFS  5,10-methenyltetrahydrofolate    NM_006441  Hs00197574_m1 
    synthetase 
TAF9   TAF9 RNA polymerase II, TATA box  NM_003187  Hs00757347_s1 
    binding protein (TBP)-associated factor, 
    32kDa 
PTPN3   protein tyrosine phosphatase,    NM_002829  Hs00160708_m1 
    non-receptor type 3 
PPIA   cyclophilin A        NM_021130  Hs99999904_m1 
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Statistical analyses have been performed using SAS software version 8 and SPSS 
software version 12.0.1. 
 
Results 
 
To obtain tumor cell related expression profiles, a high percentage of tumor cells is 
recommendable. We therefore assessed the percentage of tumor cells in all 80 biopsies. 
Thirteen tumors had a tumor cell percentage below 50% and were excluded. An 
additional 23 were excluded after evaluation of the cDNA quality using the 18S Ct. 
These were tumors that had been stored for many years and of which the RNA 
apparently had been subjected to degradation. Forty-four tumors remained, with a mean 
tumor cell content of 70% (range 50-85). 
 The group of patients consisted of 30 men and 14 women with a mean age at the time 
of diagnosis of 65.4 years (range 42 to 81). The distribution of tumor grade was: 7 GI, 33 
GII and 4 GIII. Only one patient (Pt44) received adjuvant treatment (Bacillus Calmette-
Guerin) after tumor resection. The recurrence-free interval after primary tumor resection 
was recorded for all patients and is presented in Table 2. None of the patients presented 
with concomitant carcinoma in situ. The non-recurrence (NR) and recurrence (R) group 
consisted of 21 and 23 patients respectively. 
The mRNA expression of the 26 target genes was measured in the 44 superficial Ta 
tumors by real-time Q-PCR. Their expression was normalized with cyclophilin A. The 
expression profiles of all genes are shown in Figure 1A (page 68). For comparison, the 
heatmap of the 26 genes constructed by Dyrskjøt et al. is also included (Fig. 1b; printed 
with permission). To investigate differential expression of the genes between the two 
patient groups, the expression level of each gene in the NR group (n=21) was compared 
to that in the R group (n=23) using the Wilcoxon test. This revealed statistical significant 
differences only for LTB4DH (p = 0.034) and HNRPK (p = 0.027). The statistical 
significance, however, is lost upon Bonferroni correction for multiple testing, since then 
the p-value needs to be < 0.0019 (0.05/26). Surprisingly, HNRPK expression showed an 
opposite expression pattern across both patient groups compared to the microarray 
results (Fig. 1). 
Next, we evaluated the recurrence-predictive accuracy of the panel of genes. To this 
end, the expression profiles of the most differentially expressed genes were combined 
using forward logistic regression analysis. The combination of the expression profiles of 
LTB4DH, HNRPK and ANP32B resulted in a specificity of 71.4% and a sensitivity of 
73.9% for the identification of non-recurring and recurring patients. This marginally 
increased the accuracy of HNRPK alone, which showed a specificity of 71.4% and 
sensitivity of 69.6% for the identification of patients with prolonged or short recurrence- 
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Table 2: Patient details with respect to tumor class, recurrence- 
free interval and origin of the tumor 
Patient Recurrence Tumor  Recurrence-free  Origin of 
#   Group   class  interval (months)  the tumor 
Pt1   NR    TaGI    96    Uppsala 
Pt2   NR    TaGII    204   Uppsala 
Pt3   NR    TaGII    180   Uppsala 
Pt4   NR    TaGII    120   Uppsala 
Pt5   NR    TaGII    108   Uppsala 
Pt6   NR    TaGII    108   Uppsala 
Pt7   NR    TaGII    108   Uppsala 
Pt8   NR    TaGII    84    Uppsala 
Pt9   NR    TaGII    84    Uppsala 
Pt10  NR    TaGII    72    Uppsala 
Pt11  NR    TaGII    72    Uppsala 
Pt12  NR    TaGII    72    Uppsala 
Pt13  NR    TaGII    60    Uppsala 
Pt14  NR    TaGII    60    Uppsala 
Pt15  NR    TaGIII    60    Uppsala 
Pt16  NR    TaGI    48    Uppsala 
Pt17  NR    TaGI    57    Prague 
Pt18  NR    TaGIII    54    Prague 
Pt19  NR    TaGII    51    Prague 
Pt20  NR    TaGI    69    Nijmegen 
Pt21  NR    TaGII    50    Nijmegen 
Pt22  R    TaGII    11    Uppsala 
Pt23  R    TaGII    3    Uppsala 
Pt24  R    TaGII    14    Uppsala 
Pt25  R    TaGII    4    Uppsala 
Pt26  R    TaGII    4    Uppsala 
Pt27  R    TaGIII    14    Uppsala 
Pt28  R    TaGII    5    Uppsala 
Pt29  R    TaGII    4    Uppsala 
Pt30  R    TaGIII    6    Uppsala 
Pt31  R    TaGII    12    Uppsala 
Pt32  R    TaGII    4    Uppsala 
Pt33  R    TaGII    12    Uppsala 
Pt34  R    TaGII    15    Uppsala 
Pt35  R    TaGII    4    Uppsala 
Pt36  R    TaGII    8    Uppsala 
Pt37  R    TaGII    4    Uppsala 
Pt38  R    TaGII    23    Prague 
Pt39  R    TaGII    7    Prague 
Pt40  R    TaGI    13    Prague 
Pt41  R    TaGI    7    Prague 
Pt42  R    TaGI    4    Prague 
Pt43  R    TaGII    22    Prague 
Pt44  R    TaGII    6    Nijmegen 
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free periods, respectively, when using its median expression level as cut-off. Comparison 
of the ROC curves for HNRPK expression between patients with short or prolonged 
recurrence-free periods revealed an AUC of 0.696 (95% CI, 0.537-0.855; Fig. 2). 
 
Discussion 
 
Gene expression profiling using cDNA microarray analysis contributes to our 
understanding of molecular biological changes underlying and occurring during human 
tumor cell formation and progression. Although it is a powerful technique, it is still 
relatively laborious and needs careful and complicated steps of statistical data analysis. 
The different statistical methodologies that are applied for data analysis, may hamper 
reproducibility and might also lead to considerable false discovery rates.
24
 Therefore, 
independent validation of microarray results is important, as shown recently.25 The array 
experiments should either be repeated or validated using other techniques for RNA 
expression quantification.26 One such technique is real-time quantitative PCR, which is 
well suited for the validation of potentially interesting genes in large patient cohorts. 
Reliable validation of a predictive gene panel, discovered through microarray analysis, 
by real-time Q-PCR was recently shown27, although these results were questioned 
because of the applied statistical analysis.
28
 Similarly, a two-gene predictive model for 
patients with breast discovered through microarray analysis
29
, could not be reproduced in 
a new cohort of patients.30 Despite this, examples of reliable validation of microarray 
results by PCR also exist.
31,32
 In the present study, we applied real-time Q-PCR to 
validate cDNA microarray results of Dyrskjøt et al.16 
 
 
Figure 2. The performance of HNRPK 
for the identification of patients with 
short or prolonged recurrence-free 
periods. Comparison of the receiver-
operating-characteristic curves for 
HNRPK expression between patients 
with short or prolonged recurrence-free 
periods revealed an area under the 
curve of 0.696 (95% CI, 0.537-0.855). 
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Figure 1. Comparison of the expression profiles of the 26 genes between our patient group (A) 
and that of Dyrskjøt et al. (B, reprinted by permission). The order of the genes is identical in both 
heatmaps. The microarray analysis by Dyrskjøt et al. indicated upregulation in the non-recurrence 
tumors and downregulation in the recurrence tumors for the upper genes (C1orf16-Cyr61), 
whereas the genes below (Eif3s5-Ptpn3) showed the opposite expression pattern. Expression 
levels: yellow and blue indicate higher and lower expression relative to the median (black), 
respectively. 
 
The highly discriminative gene expression pattern of the 26 genes presented by 
Dyrskjøt et al. could not be reproduced. This poor reproducibility may have several 
reasons. First, previous results indicated that for reliable validation of cDNA microarray 
results by real-time Q-PCR, two distinct tissue samples need to display at least a four-
fold difference in gene expression in the microarray experiment.
33 
The difference in the 
expression level of the 26 genes between the two groups of patients with Ta tumors 
detected by Dyrskjøt et al. is unknown. However, the difference may have been smaller 
than four-fold, since we were unable to reproduce the expression profile and showed a 
high extent of overlap of the genes between the two sets of Ta tumors. It remains a 
question whether the discrimination between the two patient groups shown by Dyrskjøt 
et al. is a result of an actual difference in the mRNA expression level or of extensive 
statistical data analysis. Whether this may also explain the difference in the HNRPK 
expression profiles needs to be elucidated. 
Second, the selection of patients may also cause differences. In the study by Dyrskjøt 
et al., only patients with a recurrence within 8 months were included in the recurrence 
group. The patients in our recurrence group also had recurrences after 8 months. 
Furthermore, we also included high-grade (grade 3) tumors in our study. To evaluate 
whether these differences caused the discrepancy between the two studies, we excluded 
all patients with recurrences after eight months (n=9) and the patients with G3 tumors 
(n=4) in two separate analyses. This did not change our results (data not shown). 
Finally, patient heterogeneity may be another plausible explanation for the lack of 
consistency. The reliable identification of (a) prognostic marker(s) and obviating patient 
heterogeneity requires extensive testing, preferably by several research groups and on 
Microarray validation in Ta UCC 
 
69
large patient cohorts. Since cDNA microarray analysis is still a laborious, complicated 
and expensive technique that needs relative large amounts of RNA, usually only a small 
number of patients is studied. Therefore, validation of potential markers, discovered 
through cDNA microarray analysis, by real-time Q-PCR may constitute an important 
step in successful hospital implementation. 
From a molecular biological perspective, it may prove difficult to discriminate 
between Ta tumors from patients who only differ with respect to their recurrence-free 
period. Ta tumors are generally much alike and arise through specific genetic alterations. 
They display similar and relatively few molecular alterations, compared to tumors of 
higher pathological stage.
34-38
 Therefore, it may not be surprising that these tumors also 
have largely similar gene expression profiles.34 Consequently, the accurate distinction 
between Ta tumors derived from patients with delayed recurrences and patients with 
early recurrences by investigating gene expression profiles poses a challenge. 
 In our study, the combination of three gene expression profiles was needed to obtain 
maximum performance with respect to the identification of early- and late-recurring 
patients. This, however, only marginally increased the performance of HNRPK alone, 
which appeared the best predictor. It may be worthwhile to investigate a combination of 
HNRPK with other genes to improve recurrence prediction in patients with Ta UCC. The 
accurate identification of patients with short- and prolonged recurrence-free periods 
using molecular markers remains a challenge and may depend on the right combination 
of several predictive genes. The role of cDNA microarray in the discovery of such genes 
may still be important, but its results need careful validation. 
 
Permissions 
 
The license for the permission to reprint Figure 1B was obtained through Copyright 
Clearance Center's Rightslink service and is placed under license number 
1347650654554. 
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Abstract 
 
The individual risk of tumor recurrence in patients with Ta UCC can not be predicted 
accurately. Therefore, all patients need regular invasive control cystoscopies. As a result, 
patients with Ta UCC who remain recurrence-free for several years will be subjected 
unnecessarily to these bladder examinations. To distinguish between patients with Ta 
UCC who remain recurrence-free for several years and those with early recurrences, we 
investigated mRNA expression of 23 genes in 44 primary Ta tumors (23 and 21 tumors 
were from patients with short or prolonged recurrence-free periods, respectively), using 
real-time quantitative PCR. The genes were selected from previously published studies 
in which they all showed a relationship with tumor recurrence in patients with UCC. 
Differential mRNA expression between the two patient groups indicated statistical 
significance only for the gene survivin (p=0.0011). Its recurrence predictive value could 
not be increased by the addition of the expression profiles of any of the other genes. 
Comparison of the receiver-operating-characteristic curves for survivin expression 
between patients with short or prolonged recurrence-free intervals revealed an area under 
the curve of 0.79 (95% CI, 0.65-0.92). Using a cut-off level of 0.24, survivin identified 
11 (52%) of the patients with prolonged recurrence-free intervals, without generating 
false-negatives (sensitivity = 100%). Thus, our study identifies survivin as the most 
promising candidate to distinguish between patients with short or prolonged recurrence-
free intervals. Therefore, survivin mRNA expression analysis might help the urologist to 
individualize patient treatment and prevent unnecessary cystoscopies in a subgroup of 
patients with Ta UCC. 
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Introduction 
 
Bladder cancer is the ninth most often diagnosed and the seventh most prevalent cancer 
worldwide.
1
 It usually presents as urothelial cell carcinoma (UCC). In approximately 
70% of newly diagnosed cases of UCC, the tumor is superficial and can be removed 
relatively easy by transurethral resection (TUR). Unfortunately, tumors will recur in a 
large part of these patients, with an additional small group showing progression to 
muscle invasive disease. Since individual prediction of recurrence or progression is 
inaccurate, tight monitoring of the bladder by invasive cystoscopy is necessary. This 
monitoring presents a burden to the patient and to treatment expenditure.
2
 Therefore, the 
accurate identification of patients who remain recurrence-free for a prolonged period of 
time would be helpful. 
Superficial UCC can be stratified in stage Ta and T1 tumors. Whereas Ta tumors 
remain confined to the urothelium, T1 tumors invade the underlying lamina propria. 
Both tumor classes are highly different with respect to their biological and clinical 
behavior.3,4 Regarding recurrence, Ta tumors generally display a lower risk of recurrence 
after primary tumor resection compared to T1 tumors.
5,6
 Other studies also show that 
patients with Ta tumors more often remain recurrence-free for several years compared to 
patients with T1 tumors.
7,8
 Generally, all patients with superficial UCC enter the same 
follow-up scheme after initial treatment by TUR. The number of unnecessary invasive 
cystoscopies is therefore highest among patients with Ta tumors. 
 Currently, the prediction of recurrence in patients with Ta tumors mainly depends on 
the assessment of tumor multiplicity and tumor size.9 Careful histological 
subclassification of Ta tumors may also be of help.10 The pathological assessment of 
tumor characteristics, however, appears to be subject to considerable observer 
variability.11,12 A more accurate test for the prediction of tumor recurrence is 
appreciated, which has resulted in the search for prognostic molecular markers. Thus far, 
only a limited number of studies used molecular markers to investigate differences in 
recurrence pattern among patients with Ta tumors, of which some showed a positive 
correlation.
13-17
 Unfortunately, these potentially useful tests have not been investigated 
further and are not integrated in clinical practice yet. 
 For the improvement of recurrence prediction in patients with Ta UCC, we 
investigated mRNA expression of 23 genes simultaneously in 44 primary Ta UCCs 
using real-time quantitative PCR (real-time Q-PCR). These 23 genes were selected from 
previous studies in which they showed a relationship between the mRNA or protein 
expression level and tumor recurrence in patients with UCC.13-16,18-34 Statistical analyses 
were applied to investigate the ability of the genes to identify patients with short or 
prolonged recurrence-free periods. 
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Materials and Methods 
 
Tumor Specimens 
In total, 80 primary Ta UCCs were selected from a consecutive collection of bladder 
tumors stored in the biobank of the Department of Urology of the University Hospital in 
Uppsala (Sweden), the Department of Urology of the Charles University in Prague 
(Czech Republic) and from the Department of Urology of the Radboud University 
Nijmegen Medical Centre in Nijmegen (The Netherlands). The tumors were selected 
from patients who experienced recurrences within two years (R-group) or who remained 
recurrence-free for at least four years. Tumors were removed by transurethral resection. 
Histopathological parameters were evaluated using the WHO criteria for grade35 and 
TNM classification for stage.
36
 All tissues were stored at -80°C. The tumors were 
collected after approval of the local ethical committees. 
 
RNA Isolation and cDNA Synthesis 
Prior to RNA isolation, the percentage of tumor cells in each biopsy was assessed. To 
this end, two 5 μM cryosections, which flanked ten 20-μM sections for RNA isolation, 
were stained with haematoxylin and eosin staining. Only biopsies containing ≥ 50% 
tumor cells were selected for our study. Initially, tumor sections were pestled in a small 
amount of TRIZol® Reagent (Invitrogen) using sterile pestles (Kimble Kontes). 
Subsequent RNA isolation was performed using TRIZol
®
 according to the manufacturers 
protocol. The isolated RNA was further purified using the RNeasy Mini Kit (Qiagen), 
during which remaining DNA was removed with the RNase-Free DNase set (Qiagen). 
RNA yield and purity were checked on a spectrophotometer at OD260 (Gene Quant pro, 
Amersham Biosciences). Reactions for cDNA synthesis contained: ~1 μg RNA, 1x PCR 
buffer (Perkin Elmer), 5.5 mM MgCl2, 0.5 mM dNTPs, 2.5 μM Random Hexamers 
(Applied Biosystems (AB)), 25 units Multiscribe (AB), 8 units RNase Inhibitor (AB), in 
a 20 μL volume. Before cDNA synthesis RNA was denatured at 95°C for 5 min. after 
which the samples were put on ice immediately. The protocol for cDNA synthesis was 
as follows: 10 min. 25°C, 30 min. 48°C and 5 min 95°C. The cDNA was stored at -20°C. 
 
Real-time Quantitative PCR 
The mRNA expression of 20 of the 23 target genes was analyzed on a 384-well format 
TaqMan® Low Density Array (LDA) using the 7900HT Fast Real-Time PCR System 
(AB). The LDA contained pre-spotted primers and probes for the detection of the 
internal RNA quality control 18S ribosomal RNA, the housekeeping gene cyclophilin A 
(for expression normalization37) and 20 target genes. The PCR reaction on the LDA was 
performed in a 2 μL volume containing 2-4 ng cDNA and 1x TaqMan® Universal PCR 
Master Mix. The mRNA expression of the other 3 target genes (Birc7, hTERT and 
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survivin) was measured separately using the ABI PRISM® 7700 Sequence Detection 
System. For the detection of hTERT and survivin we used in-house developed PCR 
assays. Primer and probe sequences and real-time Q-PCR conditions for survivin and 
hTERT detection were as described previously.32,38 The real-time Q-PCR for the 
detection of Birc7 contained 1 µL cDNA, 1x TaqMan® Gene Expression Assay and 1x 
TaqMan® Universal PCR Master Mix (No AmpErase® UNG, (AB)), in a 25 µL 
volume. An overview of the TaqMan® Gene Expression Assays used for mRNA 
expression analysis is given in Table 1. The PCR protocol for the genes on the LDA, 
survivin, hTERT and Birc7 was 10 min. 95°C and 40x(15 sec. 95°C, 1 min. 60°C). The 
expression data for the LDA and the data for the three genes measured separately were  
 
Table 1: Overview of the genes measured by real-time quantitative PCR. 
Gene             NCBI 
Symbol  Gene Full Name      RefSeq     Assay ID (AB) 
MKI67   antigen identified by monoclonal  NM_002417   Hs00606991_m1 
    antibody Ki-67 
H19   H19, imprinted maternally expressed NR_002196   Hs00399294_g1 
    untranslated mRNA 
CCND1  cyclin D1        NM_053056   Hs00277039_m1 
CD44   CD44 antigen       NM_000610   Hs00174139_m1 
KRT20   keratin 20        NM_019010   Hs00300643_m1 
CDKN1B  cyclin-dependent kinase inhibitor 1B NM_004064   Hs00153277_m1 
    (p27, Kip1) 
PCNA   proliferating cell nuclear antigen  NM_002592   Hs00427214_g1 
ECGF1  endothelial cell growth factor 1  NM_001953   Hs00157317_m1 
    (platelet-derived) 
CDKN1A  cyclin-dependent kinase inhibitor 1A NM_000389   Hs00355782_m1 
    (p21, Cip1) 
DLG7   discs, large homolog 7     NM_014750   Hs00207323_m1 
CLU   Clusterin        NM_001831   Hs00156548_m1 
MMP9   matrix metallopeptidase 9    NM_004994   Hs00234579_m1 
TIMP2   TIMP metallopeptidase inhibitor 2  NM_003255   Hs00234278_m1 
CDH1   cadherin 1, type 1, E-cadherin   NM_004360   Hs00170423_m1 
FGF2   fibroblast growth factor 2 (basic)  NM_002006   Hs00266645_m1 
TGFA   transforming growth factor, alpha  NM_003236   Hs00177401_m1 
VEGF   vascular endothelial growth factor  NM_003376   Hs00173626_m1 
BCL2   B-cell CLL/lymphoma 2    NM_000633   Hs00608023_m1 
BAX   BCL2-associated X protein    NM_004324   Hs00180269_m1 
MDK   midkine (neurite growth-promoting NM_002391   Hs00171064_m1 
    factor 2) 
BIRC7   baculoviral IAP repeat-containing 7 NM_022161   Hs01086674_g1 
    (Livin) 
PPIA   cyclophilin A       NM_021130   Hs99999904_m1 
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analyzed using the Sequence Detection System version 2.1 and Sequence Detector 
version 1.9.1. software, respectively. Only samples with an 18S ribosomal RNA Cycle 
Threshold (Ct) of < 20 were used for further analysis, because this indicated good cDNA 
quality. Target gene expression was normalized using the formula: 2 - (Ct Target- Ct cyclophilin 
A)
.
39
 
 
Heatmap Construction 
Gene expression data were uploaded into Cluster version 2.11.
40
 Genes were log-
transformed, median centered and normalized, after which the gene weights were 
calculated. Treeview was used to visualize the gene expression data.
40
 
 
Statistical Analysis 
Differences in mRNA expression between the two different patient groups (non-
recurrent (NR) and recurrent (R)) were analyzed using the Wilcoxon test, with a p-value 
< 0.05 indicating statistical significance. The Bonferroni correction (p-value of 
0.05/number of tests) was applied to correct for multiple testing. To investigate whether 
gene expression profiles  supplement each other and increase the predictive power for 
recurrence (in terms of specificity and sensitivity), forward logistic regression analysis 
was applied. Receiver-operating-characteristic (ROC) curves were created to indicate the 
performance of the genes with respect to the identification of patients with short or 
prolonged recurrence-free periods. Specificity and sensitivity refer to the identification 
of patients from the NR- and R-group, respectively. Genes were considered to have 
discriminative ability if the 95% confidence interval (95% CI) for the area under the 
curve (AUC) did not include 0.5. Statistical analyses were performed using SAS 
software version 8 and SPSS software version 12.0.1. 
 
Results 
 
A high percentage of tumor cells in biopsies favors the detection of tumor related 
expression profiles. We therefore first assessed the percentage of tumor cells in the 80 
primary Ta tumor biopsies. Thirteen tumors showed a tumor cell percentage below 50% 
and were excluded from the study. An additional 23 tumors were excluded after 
evaluating the cDNA quality of the 18S ribosomal RNA Ct value. These were tumors 
that had been stored for many years and of which the RNA apparently had been 
subjected to degradation. Forty-four tumors remained with a mean tumor cell content of 
70% (range 50-85)). 
 The remaining group of patients consisted of 30 men and 14 women with a mean 
age at the time of diagnosis of 65.4 years (range 42 to 81). The distribution of tumor 
grade was: 7 GI, 33 GII and 4 GIII. Only one patient received adjuvant treatment 
(Bacillus Calmette-Guerin) after tumor resection. The recurrence-free interval after  
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Table 2: Patient details with respect to tumor class, recurrence- 
free interval and origin of the tumor 
Patient Recurrence Tumor  Recurrence-free  Origin of 
#   Group   class  interval (months)  the tumor 
Pt1   NR    TaGI    96    Uppsala 
Pt2   NR    TaGII    204   Uppsala 
Pt3   NR    TaGII    180   Uppsala 
Pt4   NR    TaGII    120   Uppsala 
Pt5   NR    TaGII    108   Uppsala 
Pt6   NR    TaGII    108   Uppsala 
Pt7   NR    TaGII    108   Uppsala 
Pt8   NR    TaGII    84    Uppsala 
Pt9   NR    TaGII    84    Uppsala 
Pt10  NR    TaGII    72    Uppsala 
Pt11  NR    TaGII    72    Uppsala 
Pt12  NR    TaGII    72    Uppsala 
Pt13  NR    TaGII    60    Uppsala 
Pt14  NR    TaGII    60    Uppsala 
Pt15  NR    TaGIII    60    Uppsala 
Pt16  NR    TaGI    48    Uppsala 
Pt17  NR    TaGI    57    Prague 
Pt18  NR    TaGIII    54    Prague 
Pt19  NR    TaGII    51    Prague 
Pt20  NR    TaGI    69    Nijmegen 
Pt21  NR    TaGII    50    Nijmegen 
Pt22  R    TaGII    11    Uppsala 
Pt23  R    TaGII    3    Uppsala 
Pt24  R    TaGII    14    Uppsala 
Pt25  R    TaGII    4    Uppsala 
Pt26  R    TaGII    4    Uppsala 
Pt27  R    TaGIII    14    Uppsala 
Pt28  R    TaGII    5    Uppsala 
Pt29  R    TaGII    4    Uppsala 
Pt30  R    TaGIII    6    Uppsala 
Pt31  R    TaGII    12    Uppsala 
Pt32  R    TaGII    4    Uppsala 
Pt33  R    TaGII    12    Uppsala 
Pt34  R    TaGII    15    Uppsala 
Pt35  R    TaGII    4    Uppsala 
Pt36  R    TaGII    8    Uppsala 
Pt37  R    TaGII    4    Uppsala 
Pt38  R    TaGII    23    Prague 
Pt39  R    TaGII    7    Prague 
Pt40  R    TaGI    13    Prague 
Pt41  R    TaGI    7    Prague 
Pt42  R    TaGI    4    Prague 
Pt43  R    TaGII    22    Prague 
Pt44  R    TaGII    6    Nijmegen 
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primary tumor resection was recorded for all patients and is presented in Table 2. The 
NR- and R-group consisted of 21 and 23 patients, respectively. 
 After mRNA quantification of the 23 target genes, their expression was normalized 
with cyclophilin A to correct for differences in cDNA input between samples. In 
addition to the single gene measurements, the Bcl2/Bax ratio was calculated. To 
investigate differences in expression for each gene between the NR- and R-group, 
Wilcoxon analysis was applied. This revealed significant differences for Bcl2 (p = 
0.0325), hTERT and MKI67 (p-values are 0.0289), Bcl2/Bax ratio (p = 0.0225) and 
survivin (p = 0.0011). A heatmap was constructed for presentation of the gene 
expression profiles, with the best and poorest predictors at the top and bottom, 
respectively (Figure 1). Only survivin maintained statistical significance upon 
Bonferroni correction for multiple testing (Bonferroni p-value = 0.0022). Its expression 
in the NR-group and the R-group is presented in figure 2. 
To investigate the possibility of a supplementary effect of the genes with respect to 
the identification of patients with early or late recurrences, forward logistic regression 
analysis was applied. This revealed that the recurrence predictive accuracy of survivin 
could not be increased when combining its expression profile with any of the other genes 
 
 
Figure 1. Heatmap representing the expression profiles of the 23 genes across the non-recurrent 
(NR) group (n=21) and the recurrent (R) group (n=23). The genes have been ordered according to 
descending Wilcoxon p-values, with the genes above the white horizontal margin being 
statistically significantly different (p<0.05). Expression levels: Red and blue indicate higher and 
lower expression relative to the median (black), respectively. 
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Figure 2. Distribution of survivin 
expression in the NR-group and the R-
group. The boxes represent the survivin 
expression interquartile range. Open 
triangles represent outliers. The median 
survivin expression level (black 
horizontal bar) in the non-recurrent 
(NR) group and the recurrent (R) group 
are (range in parenthesis), respectively, 
0.22 (0.0025-4.35) and 1.96 (0.25-7.31). 
The difference between the two groups 
is statistically significant (p = 0.0011). 
 
 
 
 
 
showing statistical significance after Wilcoxon analysis. 
Next, the survivin test performance was evaluated. Comparison of the ROC curves 
for survivin mRNA expression between the patients with short or prolonged recurrence-
free periods revealed an AUC of 0.79 (95% CI, 0.65-0.92; Fig. 3). Using the median 
expression (0.84) as cut-off level, survivin showed a specificity of 71.4% and a 
sensitivity of 69.6% for the identification of patients with prolonged or short recurrence-
free periods, respectively. However, to accurately identify patients who will remain  
 
 
Figure 3. The performance of survivin 
for the identification of patients with 
short or prolonged recurrence-free 
periods. Comparison of the receiver-
operating-characteristic curves for 
survivin expression between patients 
with short or prolonged recurrence-free 
periods revealed an area under the 
curve of 0.79 (95% CI, 0.65-0.92). 
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recurrence-free for several years, false-negatives (i.e. patients who will develop an early 
recurrence, but who will be labeled as non-recurring) must be avoided. When we choose 
a survivin cut-off level of 0.24,  the test shows 100% sensitivity. For our group of 
patients this would mean a correct identification of 11 patients (52%) who will remain 
recurrence-free for at least four years, without generating false-negatives. 
 
Discussion 
 
We attempted to distinguish between patients with Ta UCC and short or prolonged 
recurrence-free periods by analyzing mRNA expression of 23 genes. The genes were 
selected from previously published studies in which they showed a relationship with 
tumor recurrence in patients with UCC at the protein or mRNA level. Only a few studies 
focused on patients with just Ta tumors. Despite the apparent differential ability of the 
genes in these previous studies, our analysis revealed a high degree of overlap in 
expression between patients with short and long recurrence-free periods. Only survivin 
showed significant differential expression between the two patient groups. 
 Probably the most important explanation for the high degree of overlap is that most 
of the genes we selected from the literature have been studied in a group of patients with 
both Ta and T1 tumors. Apparently, genes that have discriminative power in a group of 
Ta and T1 tumors may lack this when studied in just Ta tumors. This may not be 
surprising, since Ta and T1 tumors differ with respect to their biological and clinical 
behavior.
3,4
 Ta tumors display similar gene expression profiles which may complicate 
the identification of subgroups at the mRNA level.41 
Despite the similarity in biological behavior of Ta tumors, some studies identified 
molecular markers that were able to distinguish between patients with Ta UCC and early 
or late recurrences. One of the most important predictors of recurrence in patients with 
Ta tumors is the proliferation marker Ki67.
14
 Its protein expression level is highly 
indicative of the time to first recurrence in these patients.
14
 We measured MKI67 mRNA 
expression, which was differentially expressed between both patient groups, but did not 
accurately identify patients with short or prolonged recurrence-free periods. In addition, 
we also did not show prognostic potential for KRT20 and CD44 mRNA expression, 
although previous studies revealed a relationship between their protein level and the 
relapse-free interval in patients with Ta UCC.13,15 It thus seems that the mRNA 
expression level for these genes does not correlate well with their level of protein 
expression in Ta UCC. Therefore, prognostic information contained in a genes' protein 
expression profile, may not be accurately reflected by the corresponding mRNA 
expression profile. This may also be an additional explanation for the high degree of 
overlap of expression between our two patient groups, because several genes we selected 
from the literature have previously been studied at the protein level. 
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The aim of separating patients with Ta UCC and early or late recurrences by 
analyzing mRNA expression profiles may be facilitated by cDNA microarray analysis. 
In such analyses, thousands of genes are studied in one experiment. This has recently 
resulted in the identification of a gene panel, which discriminated between early and 
late-recurring patients with Ta UCC.
42
 We, however, have validated this 26-gene panel 
on the same cohort of tumors used in the present study and could not reproduce the 
mRNA expression profiles (see chapter 5 of this thesis). This panel, therefore, may not 
be useful in the prediction of the time to tumor recurrence. 
Our current study indicates that, at least at the mRNA level, survivin is one of the 
most promising markers for the distinction between patients with Ta UCC and short or 
prolonged recurrence-free periods. Regarding the relationship between survivin mRNA 
expression and recurrence, our findings correspond well with those of a previous study, 
in which high survivin mRNA expression indicated early recurrence in patients with Ta 
tumors.16 Therefore, increased survivin mRNA expression may help to identify patients 
who need more aggressive treatment to delay tumor recurrence. In addition, it may be 
worthwhile to determine a survivin expression threshold that can be used to identify 
patients who will remain recurrence-free for a longer period of time, without generating 
false-negatives. In our analysis, this value was set at 0.24, which correctly identified 
52% of the patients with a recurrece-free period of 4 years. In these patients the number 
of follow-up cystoscopies could be reduced significantly. The corroboration of our 
results in larger patient cohorts might relief both patient burden and treatment 
expenditure in a subgroup of patients with Ta UCC. 
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Abstract 
 
The prediction of tumor recurrence in patients with Ta urothelial cell carcinoma (UCC) 
is inaccurate, which necessitates regular examination of the bladder. A subgroup of 
patients remains recurrence-free for several years after primary surgery. Frequent 
examination of these patients generates a substantial number of unnecessary invasive 
cystoscopies. To reduce this number and relief patient burden new prognostic markers 
are desirable. To explore the prognostic potential of proteomics-based profiling 
techniques, we performed surface-enhanced laser-desorption ionization time-of-flight 
mass spectrometry (SELDI-TOF MS) on 33 primary Ta tumors (16 and 17 tumors were 
from patients with short and prolonged recurrence-free periods, respectively), and 
compared this to previously obtained mRNA expression profiles (see chapters 5 and 6 of 
this thesis). The intensities of a protein peak at m/z 33331 varied most significantly 
between the two patient groups (p = 0.0048). This was comparable to the mRNA 
expression profile of survivin, whose expression differed most significantly (p = 0.0042) 
of 49 examined genes. Receiver-operating-characteristic analysis revealed an area under 
the curve for protein peak 33331 and survivin of 0.78 (95% CI, 0.62-0.94) and 0.79 
(95% CI, 0.63-0.94), respectively, for the identification of patients with short or long 
recurrence-free periods. At specific protein and mRNA expression cut-off levels, protein 
peak 33331 and survivin identified 3 (17%) and 8 (47%) patients with a recurrence-free 
period of at least 4 years, respectively, without generating false-negatives. These 
findings indicate that SELDI-TOF MS and real-time Q-PCR analysis on the same tissue 
can result in the identification of markers with equal differential expression. Future 
research should further evaluate the importance of SELDI-TOF MS in identifying 
patients with Ta tumors who remain recurrence-free for several years. 
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Introduction 
 
The most important form of bladder cancer is urothelial cell carcinoma (UCC). It 
originates in the urothelium, which forms the inner lining of the bladder. About 70% of 
the patients with UCC are diagnosed with superficial tumors (Ta, T1), of which the 
depth of organ invasion is limited to the stromal layer below the urothelium. Therefore, 
these tumors can be removed relatively easy from the bladder by transurethral resection. 
In approximately 70% of the patients with superficial UCC tumors recur after surgery. 
Since the prediction of the individual recurrence-free period is poor, frequent control of 
the bladder of all patients by invasive cystoscopy is necessary. This also generates a 
substantial number of unnecessary bladder examinations in those patients that remain 
recurrence-free for several years or even the rest of their lives. Accurate prediction of the 
individual recurrence-free period would, therefore, limit the number of redundant 
invasive cystoscopies and reduce patient burden. 
 Patients with Ta or T1 tumors differ with respect to the risk of recurrence after 
primary tumor resection.1,2 Recurrence-free periods of several years are more frequently 
noted for patients with Ta UCC.
3-5
 The number of unnecessary control cystoscopies will 
therefore be highest among patients with Ta tumors. The prediction of recurrence in 
patients with Ta tumors mainly depends on pathologic parameters like tumor grade, 
tumor multiplicity and tumor size.
6,7
 The assessment of these tumor characteristics, 
however, is subject to observer variability.8,9 A more accurate test for the prediction of 
tumor recurrence is therefore appreciated. In recent years, research has focused on the 
prognostic potential of molecular markers.10 Thus far, only a limited number of studies 
revealed a positive correlation between such markers and the recurrence pattern among 
patients with Ta UCC.
11-16
 Unfortunately, these potentially useful tests have not been 
investigated further and are not integrated in urological practice yet. 
 To explore the prognostic potential of proteomics-based profiling techniques for 
patients with Ta UCC, protein expression profiles of 33 primary Ta UCCs were 
generated by Surface Enhanced Laser Desorption Ionisation-Time  of Flight Mass 
Spectrometry (SELDI-TOF MS). The differential expression of the protein profiles was 
compared to that of the mRNA expression profiles of 49 genes that have previously been 
obtained from the same 33 Ta tumors using real-time quantitative PCR (This thesis, 
chapters 5 and 6). In addition, the performance of differentially expressed markers, 
identified by SELDI-TOF or real-time Q-PCR, with respect to the identification of 
patients with Ta tumors who remain recurrence-free for several years after primary 
surgery was investigated. 
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Materials and Methods 
 
Tumor specimens 
Thirty-three primary Ta UCCs (Table 1) were included in this study. They have been 
obtained from the bladder tumor biobank of the Department of Urology of the 
Academical Hospital in Uppsala (Sweden), and from bladder tumor collections of the 
Department of Urology of the Charles University in Prague (Czech Republic). Tumors 
were removed by transurethral resection and histopathological parameters were 
evaluated using the WHO criteria for grade
17
 and TNM classification for stage.
18
 All 
tissues were stored at -80°C. The tumors were collected after approval of the local 
ethical committees. The biopsies contained at least 60% tumor cells as assessed by  
 
Table 1: Patient details with respect to tumor class and 
recurrence-free interval. 
Patient Recurrence  Tumor  Recurrence-free 
#   Group    class  interval (months) 
Pt1    NR    TaGI    96 
Pt2    NR    TaGII    204 
Pt3    NR    TaGII    180 
Pt4    NR    TaGII    120 
Pt5    NR    TaGII    108 
Pt6    NR    TaGII    108 
Pt7    NR    TaGII    84 
Pt9    NR    TaGII    84 
Pt10   NR    TaGII    72 
Pt11   NR    TaGII    72 
Pt12   NR    TaGII    60 
Pt13   NR    TaGIII    60 
Pt14   NR    TaGI    48 
Pt15   NR    TaGI    57 
Pt16   NR    TaGIII    54 
Pt17   NR    TaGII    51 
Pt18   R    TaGII    11 
Pt19   R    TaGII    3 
Pt20   R    TaGII    14 
Pt21   R    TaGII    4 
Pt22   R    TaGIII    14 
Pt23   R    TaGII    5 
Pt24   R    TaGIII    6 
Pt25   R    TaGII    12 
Pt26   R    TaGII    15 
Pt27   R    TaGII    8 
Pt28   R    TaGII    4 
Pt29   R    TaGII    23 
Pt30   R    TaGII    7 
Pt31   R    TaGI    7 
Pt32   R    TaGI    4 
Pt33   R    TaGII    22 
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haematoxylin and eosin staining. 
The group of patients consisted of 21 men and 12 women, with an average age of 
64.7 years (range 42-79). The distribution of tumor grade was: 4 GI, 25 GII and 4 GIII. 
No patient received adjuvant treatment after tumor resection or presented with 
concomitant carcinoma in situ. The non-recurrence (NR) and recurrence (R) group 
consist of 17 and 16 patients, respectively. Patients in the NR-group remained 
recurrence-free for 4 years, whereas those from the R-group had recurrences within the 
first 2 years after primary surgery. 
 
Protein Isolation 
The assessment of the percentage of tumor cells in the tumor biopsies, and the isolation 
of mRNA for real-time quantitative PCR analysis has been described previously 
(Chapters 5 and 6, this thesis). The proteins were isolated simultaneously with the 
mRNA from the same tumor sections using TriZol® Reagent (Invitrogen), according to 
the manufacturer's instructions. The pelleted proteins were dissolved in phosphate 
buffered saline (PBS) containing 1% sodium dodecyl sulphate (SDS). Protein 
concentrations were measured on a spectrophotometer (Gene Quant pro, Amersham 
Biosciences) at OD280. All samples were stored at -20ºC until use. 
 
SELDI-TOF MS 
To generate profiles of the isolated proteins by SELDI-TOF MS, the cation exchange 
chip CM10 (Ciphergen Biosystems, Inc) was used. This chip is optimal for profiling 
proteins dissolved in SDS, as positively charged proteins will bind to the negative 
surface of the CM10 ProteinChip surface whereas negatively charged SDS can be 
efficiently washed away.
19
 Optimization experiments revealed that a minimal protein 
concentration of 400ng/μl was necessary to generate comparable protein profiles, and 
that a  0.1 M ammonium acetate pH=3 washing buffer yielded the highest abundance of 
different protein peaks. Tumor protein profiles were generated by applying 10µl of the 
protein solution to 0.1 M ammonium acetate (pH3)-equilibrated CM10 chips, which 
were then allowed to air dry. Next, spots were washed five times with equilibration 
buffer (to remove SDS), and allowed to air dry. Finally, 0.8 µl of a saturated solution of 
sinapinic acid in 0.5% (v/v) trifluoroacetic acid and 50% (v/v) acetonitrile was applied to 
each spot surface,
 
allowed to air-dry, and reapplied. Mass/charge (m/z) spectra
 
were 
generated in a Protein Biology System II Time-of-Flight mass spectrometer (Ciphergen 
Biosystems, Inc.). Laser intensity was set to 185, 200 or 230 with detector sensitivity
 
of 
9, high mass to acquire 50 kDa, with optimization range of 5–15 kDa, 400 laser shots 
were
 
averaged to obtain the spectra. External calibration was performed using
 
Hirudin 
BKHV (7033.6 Da), bovine Cytochrome C (12230.9 Da), Myoglobin (16951.5 Da), and 
bovine Carbonic Anhydrase (29023.7 Da) as standards (Ciphergen Biosystems, Inc). 
Spectra were normalized
 
to total ion current before further analysis. Proteinchip binding 
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and SELDI-TOF MS experiments were performed in two separate sessions with samples 
randomly distributed over ProteinChip arrays. ProteinChip Software 3.0 was used for 
analysis of the mass spectra. The Biomarker Wizzard application of the ProteinChip 
Software was used for biomarker analysis. Only biomarker peaks present in at least 5 of 
the 33 spectra with a signal-to-noise ratio of 5 were used for further analysis. Biomarkers 
were only considered significant when detected at all three laser intensities with p< 0.01, 
and in at least one of these conditions with p < 0.005. 
 
mRNA Expression Analysis 
The real-time quantitative PCR (Q-PCR) analysis of mRNA expression and a detailed 
description of the 49 target genes, the housekeeping gene cyclophilin A (for expression 
normalization
20
) and the 18S ribosomal RNA subunit (for cDNA quality assessment) are 
described elsewhere (Chapters 5 and 6, this thesis). 
 
Statistical Analysis 
Differences in gene mRNA expression or protein intensities between the two different 
patient groups (non-recurrent (NR) and recurrent (R)) were analyzed using the Wilcoxon 
test, with a p-value < 0.05 indicating statistical significance. Receiver-operating-
characteristic (ROC) curves were created to indicate the performance of the markers 
with respect to the identification of patients with short or prolonged recurrence-free 
intervals. Specificity and sensitivity refer to the identification of patients from the NR- 
and R-group, respectively. Markers were considered to have discriminative ability if the 
95% confidence interval (95% CI) for the area under the curve (AUC) did not include 
0.5. Statistical analyses were performed using SPSS software version 12.0.1. 
 
Results 
 
SELDI-TOF MS 
To compare SELDI-TOF MS analysis of primary Ta tumor tissuse with real-time Q-PCR 
analysis, we wanted to generate protein profiles from the same 44 Ta tumors used in the 
previous studies that investigated mRNA expression analysis (Chapters 5 and 6, this 
thesis). However, protein extraction from 11 tumors did not yield the critical protein 
concentration of 400 ng/µl needed to generate protein profiles (see Material and Methods 
Section). SELDI-TOF MS analysis was therefore restricted to the remaining 33 Ta 
tumors (Table 1). The non-recurrence (NR) and recurrence (R) group consist of 17 and 
16 patients, respectively. The protein profiles obtained for both patient groups were 
compared to identify discriminating protein peaks. Although several protein peaks were 
found to be diferentially expressed in a small number of samples (data not shown), only 
one was considered to be significantly different in both groups. The discriminative peak 
was identified at an m/z ratio of 33331, and representative profiles showing this peak  
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Figure 1. Compa- 
rison of  33331 
protein peak 
intensities in tumors 
from the non-
recurrence (NR) and 
recurrence (R) group. 
Cell lysates were 
applied to CM10 
ProteinChips, using 
0.1 M amonium 
acetate pH3 as 
washing buffer. Mass 
spectra of retained 
proteins were 
generated by SELDI-
TOF MS. Only profiles from the four patients, which contained the 33331 protein peaks (boxed) 
with lowest (Pt19 and Pt24) and higest (Pt10 and Pt13) intensities, are shown. M/z, mass/charge 
ratio. Intensities are in arbitrary units. 
 
with highest and lowest intensities, are shown in Figure 1. As shown in Figure 2A, the 
intensity, or expression, of this protein was significantly higher in the NR-group than in 
the R-group (p = 0.0048), suggesting that reduced expression of this protein is correlated 
with a more aggressive nature of the tumor. 
Subsequently, the ability of this peak to identify patients with short or prolonged 
recurrence- free periods was investigated. The intensities of the protein peak for both 
patient  groups were compared using ROC analysis. This yielded an AUC of 0.78 (95% 
CI, 0.62-0.94; Fig. 2B). The 33331 peak displayed a respective specificity and sensitivity 
of 76% and 75% at an intensity cut-off level of 0.70. For the identification of patients 
who remain recurrence-free for at least 4 years without generating false-negatives, the 
intensity cut-off level of the 33331 peak has to be increased to 1.63. At this level the 
sensitivity is 100%, but it would  result in the correct identification of only 3 patients 
(17.6%). 
 
mRNA Expression Analysis 
The mRNA expression profiles of the 49 genes in the 33 Ta tumors were already 
available (Chapters 5 and 6, this thesis). Restriction of the Wilcoxon analysis to the 33 
tumors for the identification of differentially expressed genes revealed that survivin was 
the most significantly differentially expressed gene between the two patient groups (p = 
0.0042; Fig. 3A). Next, the performance of survivin in identifying patients with short or 
prolonged recurrence-free periods was investigated. ROC curves for survivin mRNA 
expression in both patient groups were compared and revealed an AUC of 0.79 (95% CI,  
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Figure  2.  Distribution of the 33331 protein peak intensities in the non-recurrence (NR) and 
recurrence (R) group (A) and the test performance with respect to the identification of patients 
with short or prolonged recurrence-free periods (B). (A) The boxes represent the interquartile 
range of the 33331 protein peak intensity. Open triangles represent outliers. The median intensitiy 
level (black horizontal bar) in the NR- and R-group are (range in parenthesis), respectively, 0.85 
(0.36-2.46) and 0.51 (0.23-1.61). (B) Comparison of the receiver-operating-characteristic curves 
for the 33331 peak intensities between patients with short or prolonged recurrence-free periods 
revealed an area under the curve of 0.78 (95% CI, 0.62-0.94). 
 
0.63-0.94; Fig. 3B). At a survivin cut-off level of 0.84, a specificity of 70.6% and a 
sensitivity of 81.3% for the identification of patients with prolonged or short recurrence- 
free intervals, respectively, was obtained. If we lower the cut-off level to 0.25, the test 
would correctly identify 8 patients (47%) with a recurrence-free period of 4 years, 
without generating false-negatives. 
 
Discussion 
 
Prediction of the recurrence-free period in patients with Ta UCC after primary surgery is 
still inaccurate and requires improvement. The present study was aimed at the 
comparison of the potential of SELDI-TOF MS and real-time Q-PCR to distinguish 
between patients with Ta tumors and short or prolonged recurrence-free intervals. 
SELDI-TOF MS identified a marker that was equally differentially expressed between 
the two patient groups as compared to survivin, which showed the best discriminative 
ability of the 49 mRNA markers. Still, the performance of the protein peak identified by 
SELDI-TOF MS with respect to the identification of patients with Ta tumors with 
recurrence-free periods of at least 4 years was inferior to that of survivin. 
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Figure 3. Distribution of survivin mRNA expression in tumors of the non-recurrence (NR) and 
recurrence (R) group (A) and the test perfor- mance with res- pect to the iden- tification of patients 
with short or prolonged recurrence-free periods (B). (A) The boxes represent the survivin 
expression interquartile range. Open triangles represent outliers. The median survivin expression 
level (black horizontal bar) in the NR- and R-group are (range in parenthesis), respectively, 0.32 
(0.07-4.35) and 1.99 (0.26-7.31). (B) Comparison of the receiver-operating-characteristic curves 
for survivin expression between patients with short or prolonged recurrence-free periods revealed 
an area under the curve of 0.79 (95% CI, 0.63-0.94). 
 
The number of molecular markers that show a relationship with the time to tumor 
recurrence in patients with Ta tumors is limited.
12,14-16,21,22
 In two recent reports, we 
attempted to distinguish between patients with Ta UCC who experienced their first  
recurrence within two years or who remained recurren-free for at least 4 years (Chapters 
5 and 6, this thesis). Both reports included the 33 tumors used in the present study and 
revealed that survivin was the most differentially expressed gene. Therefore, it is not 
surprising that of all 49 genes, survivin expression also varied most significantly in the 
present 33 Ta tumors. 
 Proteomic analysis of tissue for the identification of molecular markers involved in 
bladder tumorigenesis and progression is a growing field of research.
23-28
 Thus far, only 
one of these studies revealed an association between protein markers and tumor 
recurrence.
28
 SELDI-TOF MS has been used before to identify differentially expressed 
proteins between normal urothelium and tumor tissue.29 However, SELDI-TOF MS has 
not been deployed for the prediction of tumor recurrence in patients with superficial 
UCC. The present study demonstrates for the first time its ability to distinguish between 
patients with Ta UCC and short or prolonged recurrence-free periods. A peak with a m/z 
ratio of 33331 was detected and showed equal differential expression between the two 
patient groups compared to survivin mRNA expression. 
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 We did not attempt to characterize protein peak 33331. However, it should be noted 
that this peak might correspond to a double charged form of albumin (our unpublished 
observations). As albumin is a negative acute phase protein
30
, the negative correlation of 
this peak with the time to recurrence may be mediated by the more aggressive nature of 
tumors from patients with early recurrences. Interestingly, the positive acute phase C-
reactive protein was recently shown to be negatively correlated with survival of patients 
with bladder cancer31, confirming a possible predictive value of acute phase phenomena 
in bladder cancer prognosis. However, it is presently not clear what the molecular basis 
of a possible association of tumor-associated albumin and recurrence could be. 
The investigation of differences in mRNA or protein expression in the same tumor 
biopsies by two different techniques yielded two interesting markers. The analysis of 
alterations in different macromolecules, such as mRNA, protein or DNA, isolated from 
the same tumor biopt may increase the amount of prognostic information that can be 
obtained from valuable patient material. This may also result in the identification of a 
combination of markers that supplement each other and improve the prediction of the 
clinical course of patients with bladder cancer, as shown before.32 Unfortunately, ROC 
analysis of a combination of survivin and protein peak 33331 did not reveal a synergistic 
effect with respect to the prediction of tumor recurrence (data not shown). Future studies 
should demonstrate the ablility of combinations of markers to accurately predict the 
length of the recurrence-free period in patients with Ta tumors. Survivin may represent 
an interesting candidate to include in such a panel of markers, since it showed good 
performance in the identification of patients that remained recurrence-free for at least 4 
years (this study and chapter 6 of this thesis). The additional use of synergistic mRNA or 
protein markers might eventually result in a significant reduction of the number of 
unnecessary invasive cystoscopies in patients with Ta UCC. 
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Technical Brief 
 
Urothelial cell carcinoma (UCC) is the most common form of bladder cancer (1). 
Approximately 70% of the patients diagnosed with UCC have superficial tumors 
(designated Ta or T1) and are treated by transurethral resection of the tumor (TURT). 
Most of these patients develop recurrences after TURT and therefore need to be 
followed intensively. Cystoscopy is the gold standard to check the patient's bladder for 
recurrences. Unfortunately, cystoscopy is invasive, labor-intensive and costly. Accurate 
prediction of UCC recurrence could significantly reduce the number of cystoscopies 
during a patient’s follow-up period. 
Currently, the major determinants of a patient's follow-up scheme and treatment 
procedures are pathological tumor stage and grade. However, pathological assessment of 
bladder tumor stage and grade is subject to variability (2, 3). Furthermore, it is important 
to address other disease characteristics like tumor multiplicity and tumor size in order to 
carefully assess the risk of recurrence in patients with superficial UCC (4-6). For a 
possible better and more standardized estimation of the risk of recurrence in patients 
with UCC, molecular biological alterations have been studied (7-10). An important 
molecular tumor marker that emerged is survivin (11). Both the survivin protein and 
mRNA expression level in tumor tissue from patients with superficial UCC are 
indicative of the risk of tumor recurrence (12, 13). 
Assessment of prognostic parameters in UCC is usually restricted to analysis of the 
resected tumor tissue. However, routine cystoscopy frequently overlooks carcinoma in 
situ, small, solid high-grade or papillary tumors (14, 15).  These lesions may thus not be 
removed during TURT and consequently, prognostic information may be missed. As an 
advantage over tumor biopsies, bladder washings cover the entire urothelium and may 
reflect the general molecular biological status of the bladder (16-19). They are easily 
obtained during cystoscopy or prior to TURT. 
We quantified survivin mRNA expression in bladder washings by real-time 
quantitative RT-PCR. The data were correlated with histo-pathological parameters and 
with time to first recurrence in patients with superficial UCC. 
Thirty-seven 50 mL bladder washings (performed with phosphate buffered saline 
(PBS)) were collected prior to TURT from 36 patients with UCC of different stage and 
grade. The patients were asked for permission to participate in the study. After 
collection, the washings were immediately cooled on ice and the cells were harvested by 
centrifugation at 4ºC for 10 minutes at 800 xg. The cell-pellet was washed two times 
with ice-cold PBS and subsequently resuspended in ice-cold PBS, containing 1.5% fetal 
calf-serum. Bladder washings were enriched for urothelial cells to eliminate possible 
contamination with (white) blood cells, which could interfere with normalization of gene 
expression: 30 l of magnetic beads (3x107 particles) coated with an antibody (Ber-
EP4) against epithelial cells (Dynal, Oslo, Norway) was added. After incubation at 4ºC 
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for 30 minutes, bead-bound urothelial cells were washed three times with PBS 
containing 1.5% fetal calf serum. The beads were frozen in liquid nitrogen and stored at 
-80ºC. 
Histo-pathological parameters of the resected tumor tissues were evaluated by a 
pathologist according to the WHO criteria for determination of grade (20) and TNM 
classification for stage (21). The tumors of two patients were classified as superficial and 
low grade, but the pathological report did not specify stage (Ta, T1) or grade (GI, GII). 
Patients were followed clinically from the moment of tumor resection. The mean follow-
up period was 32.6 months (range 1 - 45 months). Thirteen of the 27 patients with 
superficial (Ta/T1) UCC received adjuvant treatment after TURT. The time to first 
recurrence was only determined for patients with superficial UCC. 
Isolation of total RNA from the bladder washing cells and cDNA synthesis were 
performed as described before (22). Subsequent real-time PCR quantification of survivin 
mRNA expression and, for normalization of expression, of the housekeeping gene 
cyclophilin A was performed as described previously in detail (13). The primers and the 
probe for survivin were chosen such that all three known splice variants (23) were 
detected. Real-time quantitative PCR experiments were performed with the ABI Prism 
7700 Sequence Detection System (PE Applied Biosystems). Expression of survivin and 
cyclophilin A in absolute mRNA copy numbers was performed by constructing 
linearized plasmids containing either of the amplicons. A triplicate 5-log range 
calibration curve, containing 10 to 106 copies of either survivin or cyclophilin, was 
included in each real-time PCR assay. 
Statistical analyses were performed using the Statistical Package for Social Sciences 
(SPSS), release 10.0.7 (June, 2000). Only bladder washings with a cyclophilin A copy 
number of 5 or higher were included in the analyses because this indicated sufficient 
yield of cells from the bladder washings and thus reliable quantification of survivin 
mRNA copy number. Four of the 37 bladder washings did not meet this criterion and 
were excluded from further analyses. 
First, a correlation between normalized survivin mRNA expression levels and 
pathological tumor parameters was investigated using the Kruskal Wallis test (Fig. 1A). 
The 2 patients, from whom the tumor stage and grade were not specified, were excluded 
from this analysis. Although the Kruskal Wallis p-values of 0.001 and 0.004 for tumor 
stage and grade, respectively, indicated significant differences in expression (Fig. 1A), 
no linear correlation was observed between survivin expression and increasing stage or 
grade. 
Subsequently, we investigated whether normalized survivin expression values in 
bladder washings of patients with superficial UCC can be used to distinguish patients 
with a high risk of recurrence from patients with a low risk. One patient with superficial 
UCC died one month after TURT and was excluded from the analysis, since the first 
control cystoscopy for detection of tumor recurrence is not performed earlier than three  
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Figure 1. Normalized survivin mRNA copy numbers in bladder washings (A) and Kaplan-Meier 
curves for recurrence-free survival in patients with superficial UCC (B). (A) Patients are grouped 
according to tumor stage and grade. Ta and T1, superficial tumors; T2, muscle-invasive tumors; GI 
and GII, low-grade tumors; GIII, high-grade tumors. Median normalized survivin mRNA copy 
numbers (range in parenthesis) for tumor stage and grade are as follows: Ta, 0.08 (0.01-1.84); T1, 
2.00 (0.82-4.22); T2, 0.68 (0.23-2.62); grade I (GI), 0.05 (0.01-1.84); grade II (GII), 0.1 (0.01-
1.01); and grade III (GIII), 0.92 (0.23-4.22). Survivin mRNA was detected in all bladder washings. 
Normalized survivin mRNA copy number = survivin mRNA copy number/cyclophilin mRNA 
copy number. (B) The solid line and the dashed line indicate recurrence-free survival for the 
patients whose bladder washing had a normalized survivin mRNA copy number below (n=13) or 
above (n=13) the median cut-off value of 0.13, respectively. The difference in recurrence-free 
survival between the two groups is statistically significant (log-rank test, P = 0.018). 
 
months after TURT. The 2 patients, from whom the tumor stage and grade were not 
specified, were included in this analysis, since their medical files clearly stated they 
suffered from superficial UCC. The median normalized survivin expression value of 
superficial UCCs was 0.13, which was used as the cut-off value. Kaplan-Meier curves 
were constructed for patients with a normalized survivin expression above (n=13) and 
below (n=13) the cut-off (Fig. 2). The difference between the curves was statistically 
significant (log-rank test: p=0.018). The median times to recurrence for patients with a 
normalized survivin expression above and below the median were 10 and 22 months, 
respectively. In the low and the high-risk group, 3 and 10 patients received adjuvant 
treatment after TURT, respectively. Of the patients with superficial UCC and a 
normalized survivin expression value above the cut-off (n=13), three patients died 
recurrence-free (after 3, 11 and 14 months). Eight patients had recurrences within a year 
and one had a recurrence after 14 months. Another patient remained recurrence-free 
during the follow-up. Of the patients with superficial UCC and an expression value 
below the cut-off (n=13), one patient died after 11 months (recurrence-free). Of the 
remaining 12 patients, only one had a recurrence within 12 months (after 10 months). 
The results show that bladder washings provide good quality patient material, since 
thirty-three (89.2%) of our bladder washings yielded sufficient amounts of cells for 
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reliable quantification of mRNA. The poor quality of four bladder washings may be due 
to insufficient rinsing of the bladder resulting in a low yield of cells. 
Also, a possible relationship between survivin mRNA expression in bladder 
washings and pathological tumor grade and stage was investigated. Although previous 
studies showed that mRNA or protein expression of other molecular markers in bladder 
washings can indicate UCC stage or grade (22, 24), we detected a high extent of overlap 
in the level of survivin mRNA expression between the different tumor stages (for 
example between Ta and T2) and grades (for example between GI and GII). Therefore, 
in our study, survivin mRNA expression in bladder washings did not seem directly 
indicative of UCC stage or grade. 
Interestingly, a significant relationship between normalized survivin mRNA 
expression level in the bladder washings and tumor recurrence was observed. Patients 
with superficial disease and a normalized survivin expression above the median cut-off 
value had significantly shorter recurrence-free survival periods (10 months) than patients 
with an expression below the cut-off value (22 months). We also investigated whether 
survivin mRNA could be detected in the urine from our patient group, since collection of 
urine would circumvent cystoscopy. Despite immediate processing, mRNA could not be 
detected in 50% of the urines and in cases where mRNA was quantified, no correlation 
with neither pathological nor clinical parameters was found (data not shown). 
Thus, bladder washings provide good quality patient material and the level of 
survivin mRNA expression herein may indicate whether a patient needs early or late 
control cystoscopy. If this can be confirmed in a larger cohort of patients, it may help to 
reduce the number of cystoscopies in a number of patients with superficial UCC. 
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Bladder cancer is the ninth most often diagnosed cancer worldwide, almost exclusively 
presenting as urothelial cell carcinoma (UCC). The larger part of patients with UCC is 
diagnosed with superficial tumors (Ta or T1), which are initially treated by transurethral 
resection (TUR). In about 70% of these patients tumors will recur, usually again as 
superficial lesions. In 10-15%, tumors will show progression to muscle-invasive disease 
and these patients need more aggressive treatment to control the disease in early stages. 
Therefore, frequent examination of patients with superficial UCC for tumor recurrences 
in the bladder is necessary. Cystoscopy is the gold standard for the detection of 
recurrences, but this procedure is invasive and thus presents a burden to the patient. The 
accurate discrimination between patients with short or long recurrence-free periods may, 
therefore, reduce the number of invasive cystoscopies in a subgroup of patients. 
 Current recurrence predictive parameters, like tumor grade, tumor size and tumor 
multiplicity are relatively accurate on a group level, but they are subject to differences in 
pathologic evaluation (1-3). To possibly facilitate and/or improve the prediction of the 
clinical course of patients with superficial UCC, much research has focused on the 
prognostic value of molecular markers that are deregulated in cancer cells. Many 
markers have been identified, which offer additive value to the current prognostic 
standards (4-7). Despite this, no molecular marker is integrated in urological practice 
yet. 
 Two promising molecular markers for the prediction of tumor recurrence in patients 
with superficial UCC are the proliferation marker Ki67 (encoded by the MKI67 gene) 
and the anti-apoptosis gene survivin. Increased expression of Ki67 protein and of 
survivin mRNA or protein in tumor tissue indicate short recurrence-free periods (7-15). 
We have shown, in addition to tumor tissue, a relationship between early tumor 
recurrence and elevated levels of survivin mRNA in bladder washings obtained from 
patients treated by TUR for superficial tumors (16). Bladder washings are easily 
obtained during cystoscopy and generally reflect the molecular biological status of the 
urothelium (17, 18). They may also provide additional prognostic information compared 
to tumor biopsies, since these washings reflect the status of the entire urothelium. 
 To confirm our previous findings regarding survivin, and to investigate the 
recurrence-predictive value of MKI67 mRNA expression, we collected bladder washings 
from a new cohort of patients treated by TUR for superficial tumors. The mRNA 
expression levels of both genes were measured by real-time quantitative PCR (Q-PCR). 
A correlation between the expression data and the pathologic tumor parameters stage and 
grade, and with the clinical parameter recurrence was investigated by statistical analysis. 
From 75 patients, undergoing TUR at the Department of Urology of the Radboud 
University Nijmegen Medical Center in Nijmegen (The Netherlands), 95 bladder 
washings were obtained. The bladders were rinsed approximately 5 times with 50 mL 
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phosphate buffered saline (PBS) just prior to TUR. The collection of the cells was 
performed as described previously, except that the elaborate enrichment for urothelial 
cells was omitted (16). 
 Subsequently, RNA was isolated from the cells using TRIZol® Reagent (Invitrogen) 
according to the manufacturer’s protocol. RNA yield and purity were checked on a 
spectrophotometer at OD260 (Gene Quant pro, Amersham Biosciences). The RNA input 
for cDNA synthesis varied from ~100 ng to ~1 µg, depending on the total RNA yield. 
The protocol for cDNA synthesis was described previously (16). 
 To determine the cDNA quality of all samples, mRNA expression of cyclophilin A 
was measured in 1 µL cDNA by real-time Q-PCR using the ABI-PRISM
®
 7700 
Sequence Detection System (Applied Biosystems (AB)). The PCR reaction further 
contained 1x TaqMan® Universal PCR Master Mix (No AmpErase® UNG (AB)) and 
1x cyclophilin A TaqMan® Endogenous Control (containing primers and a VIC-Tamra 
probe for detection (AB)), in a 25 µL volume. The real-time PCR protocol was 10 min. 
95°C and 40x(15 sec. 95°C, 1 min. 60°C). Expression data were analyzed using 
Sequence Detector version 1.9.1. software (AB). Twenty-seven (28,4%) samples with a 
cyclophilin Cycle Threshold (Ct) above 34 were excluded, because this indicates 
insufficient cDNA quality. 
 Next, the pathologic reports from the 68 remaining TURs were evaluated. This 
resulted in the exclusion of another 11 bladder washings (5 collected from patients 
without a tumor, 5 from patients with invasive tumors and 1 from a patient with an 
adenocarcinoma). A final number of 57 bladder washings, obtained from 47 different 
patients, remained. A maximum of 2 bladder washings per patient were analyzed. The 
group consisted of 36 men and 11 women with a mean age at the time of the first TUR 
of 67 years (range 45-82). The follow-up period ranged from 6-35 months, during which 
29 patients developed a recurrence and the other 28 remained recurrence-free. In 12 and 
27 patients tumors recurred within 1 or 2 years after surgery, respectively. The 
recurrence-free period was recorded from the moment of the TUR prior to which a 
bladder washing was collected. The pathologic and treatment characteristics of the 
bladder washings are presented in Table 1. 
We then measured survivin and MKI67 mRNA expression in the 57 remaining 
bladder washings. The real-time Q-PCR conditions and the primers and probe for 
survivin detection were as published previously (13). The PCR conditions and contents 
for MKI67 detection were as described for cyclophilin A, except that 1x MKI67 
TaqMan
®
 Gene Expression Assay (Assay ID Hs00606991_m1 (AB)), for MKI67-
specific detection, was added. Data analysis for both genes was as described for 
cyclophilin A. Survivin and MKI67 gene expression were normalized with cyclophilin A 
expression, using the formula 2 - (Ct Target- Ct cyclophilin A) (19). For statistical analysis of the 
data, the Statistical Package for Social Sciences (SPSS) version 12.0.1 was used. 
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First, a correlation between survivin 
and MKI67 mRNA expression in the 
bladder washings and the corresponding 
pathologic parameters stage and grade of 
the resected tumor tissue was 
investigated, using the Mann-Whitney U 
test (stage) and the Kruskal-Wallis test 
(grade). The mRNA expression of both 
genes showed a clear correlation with 
pathologic characteristics (Fig. 1). 
Next, a relationship between the 
mRNA expression level of both genes 
and the time to tumor recurrence was 
investigated. Kaplan-Meier survival 
curves were constructed for patients with 
Ta and T1 tumors and survivin or 
MKI67 mRNA expression below and 
above the median. The curves were 
compared with the log-rank test. Neither 
survivin nor MKI67 expression 
correlated with the recurrence-free 
period (log-rank p-values are 0.88 and 
0.21, respectively). We performed the 
same analysis for the patients with Ta 
tumors only, but again no correlation 
was detected (log-rank p-value = 0.11 
for both genes). Of the parameters tumor stage, grade and tumor multiplicity, only grade 
showed a relationship with tumor recurrence in Kaplan-Meier analysis in the entire 
cohort of bladder washings (log-rank p-value = 0.012). A significant difference with 
respect to the recurrence-free interval was only seen between patients with G1 and G2 
tumors (log-rank p-value = 0.003). 
In contrast to the present results, we previously detected a correlation between the 
survivin mRNA expression level in bladder washings and the recurrence-free interval 
(16). In this previous study bladder washings were enriched for urothelial cells to 
prevent interference of gene expression normalization by non-urothelial cells, especially 
white blood cells. We omitted the elaborate enrichment step in the present study, 
because this significantly simplifies the whole procedure. Unfortunately, the omission 
may have resulted in the loss of a correlation between survivin mRNA expression and 
the time to tumor recurrence. Future automation of the enrichment step would favor its 
inclusion in the routine analysis of bladder washings and may revert the correlation  
Table 1. Pathologic and treatment characac-
teristics of the bladder washings, obtained 
from 47 patients with superficial UCCa 
        No (%) 
Bladder Washings   57 (100) 
Stage Ta      48 (84.2) 
  T1      9 (15.8) 
Grade 1      21 (36.8) 
  2      25 (43.9) 
  3      11 (19.3) 
Multiplicity 
  Single     16 (28.1) 
  Multiple    41 (71.9) 
Therapyb      47 (82.5) 
  Mitomycin C   14 (29.8) 
  BCGc     10 (21.3) 
  EOquind    9 (19.1) 
  Synergoe    7 (14.9) 
  Epirubicine   4 (8.5) 
  Immucothel   2 (4.3) 
  Gemcitabine   1 (2.1) 
aUCC = Urothelial Cell carcinoma 
bTherapy (all 7 together) did not affect the time to 
tumor recurrence (log rank p-value = 0.69) 
cBCG = Bacillus Calmette Guérin 
d
Eoquin is a derivative of Mitomycin C 
e
Synergo is a combination of hyperthermia and 
Mitomycin C 
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Figure 1. Distribution of survivin (A) and MKI67 mRNA expression (B) in the 57 bladder 
washings. The boxes represent the interquartile range. Open triangles represent outliers. The 
median gene expression levels (thick black horizontal bar) are (range in parenthesis), survivin: Ta, 
0.18 (0.002-2.27); T1, 0.87 (0.14-4.44); G1, 0.07 (0.002-1.95); G2, 0.21 (0.05-2.68); G3, 0.66 
(0.31-4.44), and MKI: Ta, 0.20 (0.02-3.23); T1, 0.90 (0.21-6.5); G1, 0.10 (0.02-2.73); G2, 0.41 
(0.02-3.63); G3, 0.72 (0.31-6.45). The survivin and MKI67 expression levels were normalized 
with cyclophilin and calculated using the formula 2-(CtTarget-CtCyclophilin).  
 
between survivin expression levels and the length of the recurrence-free interval. It also 
remains to be elucidated whether this holds for MKI67 as well. 
Despite the lack of a correlation with recurrence, survivin and MKI67 mRNA 
expression in the bladder washings correlated nicely with the pathologic parameters 
stage and grade of the corresponding resected tumor tissues. Therefore, even in the 
absence of enrichment for urothelial cells, bladder washings may provide an accurate 
profile of the molecular biological status of the urothelium from patients with superficial 
UCC. Currently, treatment decision-making by the urologist relies strongly on the 
pathologic assessment of tumor stage and grade. Since tumors may be missed during 
cystoscopy and pathologic assessment of tumor stage and grade is error-prone, the 
measurement of survivin or MKI67 mRNA in bladder washings could aid the pathologist 
in the determination of tumor stage and grade. When this results in a more accurate 
tumor classification, it might assist the urologist in patient treatment desicion-making. 
 
References 
1. Bol MG, Baak JP, Buhr-Wildhagen S, Kruse AJ, Kjellevold KH, Janssen EA, et al. 
Reproducibility and prognostic variability of grade and lamina propria invasion in stages Ta, T1 
urothelial carcinoma of the bladder. J Urol 2003;169:1291-4. 
Chapter 9 
 
112
2. Kiemeney LA, Witjes JA, Heijbroek RP, Verbeek AL, Debruyne FM. Predictability of recurrent 
and progressive disease in individual patients with primary superficial bladder cancer. J Urol 
1993;150:60-4. 
3. Tosoni I, Wagner U, Sauter G, Egloff M, Knonagel H, Alund G, et al. Clinical significance of 
interobserver differences in the staging and grading of superficial bladder cancer. BJU Int 
2000;85:48-53. 
4. van Rhijn BW, Lurkin I, Radvanyi F, Kirkels WJ, van der Kwast TH, Zwarthoff EC. The 
fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder 
cancer with low recurrence rate. Cancer Res 2001;61:1265-8. 
5. van Rhijn BW, Vis AN, van der Kwast TH, Kirkels WJ, Radvanyi F, Ooms EC, et al. Molecular 
grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior 
to pathologic grade for the prediction of clinical outcome. J Clin Oncol 2003;21:1912-21. 
6. Yamamoto Y, Matsuyama H, Furuya T, Oga A, Yoshihiro S, Okuda M, et al. Centrosome 
hyperamplification predicts progression and tumor recurrence in bladder cancer. Clin Cancer Res 
2004;10:6449-55. 
7. Tada Y, Wada M, Taguchi K, Mochida Y, Kinugawa N, Tsuneyoshi M, et al. The association of 
death-associated protein kinase hypermethylation with early recurrence in superficial bladder 
cancers. Cancer Res 2002;62:4048-53. 
8. Asakura T, Takano Y, Iki M, Suwa Y, Noguchi S, Kubota Y, et al. Prognostic value of Ki-67 
for recurrence and progression of superficial bladder cancer. J Urol 1997;158:385-8. 
9. Ku JH, Kwak C, Lee HS, Park HK, Lee E, Lee SE. Expression of survivin, a novel inhibitor of 
apoptosis, in superficial transitional cell carcinoma of the bladder. J Urol 2004;171:631-5. 
10. Oosterhuis JW, Schapers RF, Janssen-Heijnen ML, Smeets AW, Pauwels RP. MIB-1 as a 
proliferative marker in transitional cell carcinoma of the bladder: clinical significance and 
comparison with other prognostic factors. Cancer 2000;88:2598-605. 
11. Pich A, Chiusa L, Formiconi A, Galliano D, Bortolin P, Comino A, et al. Proliferative activity 
is the most significant predictor of recurrence in noninvasive papillary urothelial neoplasms of low 
malignant potential and grade 1 papillary carcinomas of the bladder. Cancer 2002;95:784-90. 
12. Santos L, Amaro T, Costa C, Pereira S, Bento MJ, Lopes P, et al. Ki-67 index enhances the 
prognostic accuracy of the urothelial superficial bladder carcinoma risk group classification. Int J 
Cancer 2003;105:267-72. 
13. Schultz IJ, Kiemeney LA, Witjes JA, Schalken JA, Willems JL, Swinkels DW, et al. Survivin 
mRNA expression is elevated in malignant urothelial cell carcinomas and predicts time to 
recurrence. Anticancer Res 2003;23:3327-31. 
14. Swana HS, Grossman D, Anthony JN, Weiss RM, Altieri DC. Tumor content of the 
antiapoptosis molecule survivin and recurrence of bladder cancer. N Engl J Med 1999;341:452-3. 
15. Weikert S, Christoph F, Schrader M, Krause H, Miller K, Muller M. Quantitative analysis of 
survivin mRNA expression in urine and tumor tissue of bladder cancer patients and its potential 
relevance for disease detection and prognosis. Int J Cancer 2005;116:100-4. 
16. Schultz IJ, Kiemeney LA, Karthaus HF, Witjes JA, Willems JL, Swinkels DW, et al. Survivin 
mRNA copy number in bladder washings predicts tumor recurrence in patients with superficial 
urothelial cell carcinomas. Clin Chem 2004;50:1425-8. 
Survivin and MKI67 expresion in bladder washings 
 
113
17. Acar H, Kilinc M, Yildirim MS, Kaynak M, Cenker A. Evaluation of chromosome 8 and 11 
aneuploidies in washings and biopsy materials of bladder transitional cell carcinoma. Cancer 
Genet Cytogenet 2003;142:25-9. 
18. Vet JA, Hessels D, Marras SA, van de Kaa CA, van der Poel HG, Michalides RJ, et al. 
Comparative analysis of p53 mutations in bladder washings and histologic specimens. Am J Clin 
Pathol 1998;110:647-52. 
19. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time 
quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001;25:402-8. 
 114
 
115 
Chapter 10 
 
 
 
Summary, General Discussion & 
Future Perspectives 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 10 
 
116
Summary 
 
The high risk of tumor recurrence in patients with superficial urothelial cell carcinoma 
(UCC; Ta and T1 tumors) necessitates frequent examination of the bladder by invasive 
cystoscopies. This will also, unfortunately, result in a substantial number of unnecessary 
bladder examinations, because a subgroup of patients will remain recurrence-free for 
several years or even the rest of their lives after primary tumor resection. Therefore, the 
accurate prediction of the time to first tumor recurrence is of eminent importance to 
reduce the number of invasive cystoscopies and support treatment decision-making. 
Ultimately, this could result in a significant reduction of the burden to the patient, the 
clinic and treatment expenditure. 
 The current pathological parameters fall short in the prediction of tumor recurrence 
in patients with superficial UCC on the individual level. In recent years, much research 
has focused on the discovery of molecular markers that may supplement or even replace 
the current prognostic standards. Although many seem predictive of the recurrence-free 
period, none has been implemented in urological practice yet. The mainspring for the 
research presented in this thesis was the significant progress that can still be achieved in 
the prediction of the time to tumor recurrence in patients with UCC. The next section 
will summarize the findings in the various chapters. 
  The chapters 2, 3 and 4 describe the prognostic value of survivin, CDC91L1 and 
STK15 in patients with superficial and invasive UCC. In chapter 2, mRNA expression of 
the anti-apoptosis gene survivin was investigated in bladder tumor tissue varying in stage 
and grade. A correlation was detected between the level of surivin mRNA expression 
and the malignancy state of the tumor, i.e. stage and grade. Although the survivin mRNA 
expression level did not correlate with tumor progression or survival, patients with early 
tumor recurrences displayed significantly elevated levels of survivin mRNA in their 
tumors. These findings indicate that survivin may be a useful marker for the prediction 
of the time to tumor recurrence and might assist treatment decision-making in patients 
with superficial UCC. 
Chapter 3 describes the mRNA expression pattern of CDC91L1 (PIG-U) in UCC 
tissues of different malignancy stage and grade, normal urothelium and bladder cancer 
cell lines. This research was conducted in response to the finding by Guo et al. (Nat. 
Med. 2004;10:374-381), which showed an important oncogenic role for this gene in 
bladder cancer. Whereas they detected overexpression of CDC91L1 mRNA in 36% of 
the tumors, we showed overexpression in only 2.4%. In addition, the CDC91L1 
expression level did not show a relationship with pathological tumor stage or grade, nor 
with the clinical parameters recurrence, progression and survival. Our findings contradict 
CDC91L1 overexpression in bladder cancer and warrant further investigation of its 
expression profile in this disease. The latter should answer the question whether 
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CDC91L1 can be an interesting therapeutic target in bladder cancer, as suggested by 
Guo et al. 
The prognostic value of the T91A polymorphism in the STK15 gene, and its mRNA 
expression in patients with superficial and invasive UCC is described in chapter 4. On 
the DNA level, we did not detect any prognostic information regarding the STK15 T91A 
polymorphism in our patient cohort. In contrast, STK15 mRNA expression increased 
significantly with increasing tumor stage and grade. Moreover, patients with elevated 
levels of STK15 mRNA displayed an increased risk of tumor recurrence in the first year 
after tumor resection. High STK15 expression was also associated with an increased risk 
of tumor progression. Finally, patients showed decreased overall and UCC-specific 
survival if their tumors expressed elevated STK15 mRNA levels. The notion that 
patients with UCC and high STK15 mRNA expression in their tumors generally show a 
more adverse disease course, may pinpoint STK15 as an interesting therapeutic target in 
this disease. 
The relationship between survivin mRNA expression and the time to tumor 
recurrence (see chapter 2 of this thesis), and the current lack of a reliable marker for the 
prediction of tumor recurrence in patients with superficial UCC, led us to concentrate on 
this specific field of research. We focused on patients with Ta tumors (least invasive 
tumors), since a substantial part of these patients remains recurrence-free for several 
years but is still subject to frequent invasive bladder examinations that contribute to 
patient burden and treatment expenditure. The chapters 5, 6 and 7 describe the prediction 
of the time to tumor recurrence in patients with Ta tumors. The gene mRNA expression 
analysis presented in chapter 5 was performed in response to the cDNA microarray study 
by Dyrskjøt et al. (Nat. Genet. 2003;33:90-96). They discriminated between patients 
with Ta UCC and early or late recurrences using a 26-gene panel. We validated this 
panel in another group of patients with Ta UCC and short or long recurrence-free 
periods, using real-time quantitative PCR. Surprisingly, the concordance between their 
expression profile and ours was very poor. Only one gene, HNRPK, showed reasonable 
differential expression between the two patient groups, but its performance in identifying 
patients with short or prolonged recurrence-free periods fell short. In addition, its 
expression profile was opposite to the data of Dyrskjøt et al. Since our study population 
resembled that of Dyrskjøt et al. to a high extent, it is difficult to pinpoint a cause for the 
difference in expression pattern between the two studies. This discrepancy demonstrates 
the importance of validating  cDNA microarray results in additional patient cohorts and 
by other techniques. 
In chapter 6, mRNA expression of 23 genes was investigated in the same 44 primary 
Ta tumors described in chapter 5. The genes were selected after a careful study of the 
literature on the basis of a relationship with tumor recurrence in patients with UCC. 
Statistical analysis of our data showed that only survivin displayed significant 
differential expression between patients with short or long recurrence-free periods. Its 
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expression profile displayed a specificity of 71% and a sensitivity of 70% for the 
identification of patients with long or short recurrence-free intervals, respectively. 
Interestingly, at a cut-off level of 0.24, survivin detected 52% of the patients who 
remained recurrence-free for at least 4 years, without generating false-negatives. The 
results provide additional evidence to the findings in chapter 2 that survivin could be an 
interesting recurrence-predictive marker in patients with superficial UCC. 
From 33 of the 44 Ta tumors analyzed in chapters five and six, protein profiles were 
generated using Surface Enhanced Laser Desorption Ionisation-Time of Flight Mass 
Spectrometry (SELDI-TOF MS). This is presented in chapter 7. The performance of 
these protein profiles with respect to the identification of patients with short or long 
recurrence-free periods was compared to that of the mRNA expression profiles of the 49 
genes analyzed in chapters five and six. One of the protein peaks identified by SELDI-
TOF, with an m/z ratio of 33331, showed equal differential expression between the two 
patient groups compared to survivin. However, the performance with respect to the 
identification of patients with short or long recurrence-free periods was poorer than that 
of survivin. Also, the combination of survivin and protein peak 33331 did not improve 
recurrence prediction. Future experiments should prove whether the simultaneous 
analysis of a single tumor biopsy with different techniques can yield a combination of 
markers that provides better prognostic performance compared to a single marker. 
Finally, chapters 8 and 9 evaluated the utility of bladder washings for the prediction 
of recurrence in patients with superficial UCC. Bladder washings appear a useful 
alternative to tumor tissue and may have an added value to tumor tissue, because they 
cover the entire lining of the bladder. Chapter 8 evaluated mRNA expression of survivin 
in bladder washings enriched for urothelial cells, in order to prevent interference with 
gene expression normalization by non-urothelial cells. Although the level of survivin 
mRNA expression did not correlate well with pathological tumor stage and grade, it 
showed a relationship with the time to tumor recurrence. This indicated that bladder 
washings may be useful for prognostic purposes and might circumvent the need for the 
selection of tumor tissue. 
Chapter 9 describes the analysis of survivin and MKI67 mRNA expression in a new 
cohort of bladder washings obtained from patients with superficial UCC. In contrast to 
chapter 8, the elaborate step of urothelial cell enrichment was omitted in order to 
simplify and shorten the whole procedure. This may facilitate implementation in routine 
practice. A nice correlation between increased survivin and MKI67 mRNA expression 
and higher tumor stage and grade was detected. Unfortunately, no relationship between 
the gene expression levels and the recurrence-free interval was shown. This may be 
attributable to the omission of the enrichment step or the loss of a substantial number of 
bladder washings (n=27) due to a poor quality. The latter may have influenced the 
composition of the study population with respect to the recurrence pattern. On the other 
hand, the clear correlation of the mRNA expression of both genes with tumor stage and 
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grade indicates that bladder washings seem to reflect the molecular state of the bladder. 
The possible prognostic utility of bladder washings needs further investigation. 
 
 
General Discussion 
 
Research into mapping the molecular biological alterations occurring during 
tumorigenesis has increased immensely over the past years. Many studies have identified 
alterations in the mRNA or protein expression level of hundreds of genes or identified 
changes at the DNA level that distinguish normal healthy cells from tumor cells [1]. In 
addition, these so-called molecular markers also seem helpful in the distinction between 
less aggressive and highly malignant tumors. This has resulted in the accurate 
discrimination between patients with a favorable disease course from those with a more 
adverse perspective, for example in the case of breast cancer [2], lung cancer [3], colon 
cancer [4] and bladder cancer [5]. It has, however, proven rather difficult to integrate 
promising predictive single or panels of markers into clinical practice [6]. 
 In many cases molecular markers prove successful when tested in a single cohort of 
patients, but when validated in another patient cohort they often show reduced predictive 
capability. The larger part of the prognostic markers that are mentioned in the 
introduction (chapter 1, section 2.3) showed rather poor reproducibility in other studies 
or have not been validated at all. The frequent poor reproducibility of molecular markers 
is nicely illustrated by the chapters 3 and 5 of this thesis in which an, afterwards, 
unsuccessful attempt was made to validate the promising marker CDC91L1 [7] and a 
discriminative panel of markers [8], respectively. The repeated lack of consistency in the 
predictive capability of molecular markers can largely be attributed to patient, or tumor, 
heterogeneity. The differences in genetic background in combination with differences in 
life style render all patients unique. It may, therefore, not be surprising that the 
biological state of a molecular marker can prove highly variable between patients. 
 Besides patient heterogeneity as a cause for the frequent inconsistent prognostic 
value of molecular markers, the complexity of the test that determines its biological state 
can also affect reproducibility. A marker can have excellent disease characteristics, for 
example a significantly different mRNA or protein expression level between two 
clinically relevant patient groups. However, when the test that assesses its biological 
state is highly complicated, other research groups may encounter difficulties in repeating 
the test. If this leads to inconsistent results, the test, and thus the marker, may not be 
suitable for implementation in routine clinical practice. In light of this, real-time 
quantitative PCR, the main technique applied in the research presented in this thesis, for 
the detection of mRNA has some advantages. It is an automated technique, which 
renders the data generation and read-out straightforward and delivers reproducible 
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results [9]. Additionally, standardized PCR assays for all human genes are commercially 
available. This favors comparison of the results obtained by different research groups. In 
combination with a standardized procedure for the isolation of mRNA from tissue, real-
time quantitative PCR may comprise a highly suitable technique for the use in 
prognostic studies. 
 Despite the obstacles molecular markers need to overcome before they are 
considered potentially interesting, some seem promising. The recurrence-predictive 
capability of survivin in patients with superficial bladder cancer, for example, appears 
reproducible. Its protein or mRNA expression has been tested in nine different cohorts of 
patients with superficial UCC, of which eight investigated a relationship with tumor 
recurrence. In seven (including the chapters 2, 6 and 8 of this thesis) of these eight 
studies, a positive correlation was detected between the level of survivin expression and 
the length of the recurrence-free period [10-15, and chapter 6 of this thesis]. On the other 
hand, only one study showed prognostic value for survivin independent of the 
pathological parameters stage and grade [10]. The other studies indicated that survivin 
may only supplement pathology in predicting the time to tumor recurrence. Although the 
results for survivin seem promising, it can not yet compete with the proliferation marker 
Ki67, which has repeatedly proven an independent predictor of the length of the 
recurrence-free interval in patients with superficial UCC [16-20]. 
 Studies that evaluate the value of a specific molecular marker for the prediction of 
the time to tumor recurrence in patients with superficial bladder cancer also need to 
address another important issue, i.e. the resection of tumor tissue by the urologist. In a 
substantial part of patients with Ta (20-30%) or T1 (30-60%) tumors, residual tumor 
tissue can be found in the bladder after the initial resection [21-24], which is largely due 
to incomplete resection. It is likely that the unresected tumor tissue gives rise to a new 
tumor that may actually be labeled as a recurrence during the first control cystoscopy, 
which is generally planned three months after primary tumor resection. However, this 
period is generally too short for neoplastic urothelial cells to give rise to a whole new 
tumor in patients diagnosed with low-grade (G1 and G2) superficial bladder cancer. It is, 
therefore, important to assess the location of the recurrent tumor in relation to the time 
after primary tumor resection. This will eventually provide a more accurate picture of the 
recurrence-predictive capability of a molecular marker. 
 In the studies presented in this thesis, careful attention has been given to the 
difference between ‘new’ tumors and tumors that may have been influenced by 
incomplete tumor tissue removal. However, it can not be ruled out that in some cases 
'recurrent' tumors have mistakenly been labeled as new. Small tumors, for example, can 
be overlooked during the initial tumor resection and may be recorded as a new tumor at 
first follow-up cystoscopy. Overlooking small tumors represents a flaw that concerns all 
research regarding the prediction of tumor recurrence in patients with superficial UCC, 
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but since it is a universal problem it may not affect the mutual comparison of the 
different studies. 
 
 
Future Perspectives 
 
As depicted in the general discussion of this thesis, the reproducibility of molecular 
markers is an important issue that needs to be addressed before safe implementation into 
clinical practice. This also accounts for the markers that have been evaluated in the 
chapters presented in this thesis. It is therefore recommended to test them on new, 
preferably large patient cohorts. This may indicate whether a marker behaves 
consistently throughout a wide range of bladder tumors from patients with the same 
clinical endpoint, for example early or late recurrence. Additionally, the test that assesses 
the biological state of the marker should be simple, which will also favor reproducibility. 
The latter may be of crucial importance when a marker is tested in a multicenter study, 
since this requires accurate mutual comparison of the results from different research 
groups. Real-time quantitative PCR may constitute an interesting technique in such 
studies, since it provides reproducible results due to the high level of standardization. 
 The promising results for survivin in predicting the time to tumor recurrence in 
patients with superficial tumor recurrence may warrant additional studies. Interestingly, 
the results described in the chapters 2, 6 and 8 of this thesis have encouraged the 
Department of Urology of the Radboud University Nijmegen Medical Centre to initiate a 
large prospective study to evaluate the predictive value of survivin mRNA expression in 
tumor tissue of patients with superficial UCC. It is recommended, in light of the often 
incomplete removal of tumor tissue (see general discussion of this thesis), to perform a 
control TUR three months after primary tumor resection in all patients included in the 
study. This will be of crucial importance to those patients that survivin identifies as 
‘recurrence-free for several years’, since these patients should be free of tumor tissue 
after primary surgery. To determine whether survivin predicts tumor recurrence 
independent of pathology, its prognostic value should be compared to other recurrence 
predictive parameters like tumor grade, tumor size and tumor multiplicity. This should 
illustrate the possibility of implementing survivin in clinical practice. 
 In more recent years, the notion that single markers may not be all informative has 
gained increasing attention. The identification of gene-panels, through techniques like 
cDNA microarray, that distinguish between clinically relevant subgroups of patients 
have been presented in many studies. Still, these panels also need careful validation in 
new patient cohorts (see also chapter 5 in this thesis). Thus far, the gene-panels do not 
appear superior to the single markers, and both compete only occasionally with 
pathological parameters. Extensive additional research will prove whether the current 
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pathological parameters that are still widely used for the prediction of the clinical course 
of patients with superficial UCC can eventually be supplemented or even replaced by 
molecular markers. 
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Samenvatting 
 
De belangrijkste vorm van blaaskanker is urotheelcel carcinoom (UCC). Patiënten met 
UCC waarvan de tumoren oppervlakkig zijn (de zogenaamde Ta en T1 tumoren) kunnen 
relatief makkelijk geopereerd worden, omdat de tumoren niet diep in het blaasweefsel 
zijn ingegroeid. Maar deze patiënten hebben wel een erg hoog risico op het terugkeren 
van tumoren in de blaas nadat ze geopereerd zijn. Deze terugkerende tumoren, ook wel 
recidieven genoemd, maken het noodzakelijk dat de patiënten regelmatig terug moeten 
komen naar het ziekenhuis voor controle. De controle van de blaas op recidieven wordt 
uitgevoerd m.b.v. cystoscopie, een procedure waarbij de arts, in dit geval de uroloog, 
met een camera de blaas van binnenuit inspecteert op de aanwezigheid van tumoren. 
Deze handeling is een vervelende belasting voor de patiënt en bovendien erg duur. Naast 
de groep patiënten die snel een recidief krijgen na de operatie, is er ook een groep die na 
de verwijdering van de tumoren een aantal jaren en soms de rest van hun leven 
recidiefvrij blijft. Omdat niet precies voorspeld kan worden welke patiënt lang en welke 
maar kort recidiefvrij blijft, worden alle patiënten regelmatig onderworpen aan de 
belastende cystoscopie. Bij de patiënten die lang recidiefvrij blijven zal dus een 
aanzienlijk aantal onnodige cystoscopieën uitgevoerd worden. Als de tijd tot het eerste 
recidief nauwkeurig voorspeld kan worden, kan dit een aanzienlijke reductie van het 
aantal onnodige cystoscopieën en een afname in de behandelingskosten betekenen. 
 De uroloog probeert aan de hand van een aantal kenmerken van een patiënt in te 
schatten hoe groot het risico op het krijgen van (snelle) recidieven is. Het belangrijkst 
hierbij is de informatie van de patholoog, die nauwkeurig het tumorweefsel dat de 
uroloog uit de patiënt heeft verwijderd bestudeert. Daarbij kijkt de patholoog naar het 
stadium van de tumor (hoe ver is de tumor in de blaas ingegroeid), naar de graad van de 
tumor (hoe meer de tumorcel afwijkt van een gezonde cel, hoe agressiever deze is en hoe 
hoger de graad), en naar het aantal en de grootte van de tumoren. Deze zogenaamde 
pathologische parameters geven de uroloog een indruk van het risico dat een patiënt 
heeft om snel weer een tumor in de blaas te krijgen na een operatie. Maar deze 
parameters schieten tekort, want ze helpen wel om patiënten in een bepaalde risicogroep 
in te delen, maar zijn onbetrouwbaar als het gaat om het inschatten van het individuele 
risico van een patiënt. Daarom proberen onderzoekers een betere methode te vinden om 
te voorspellen wanneer een patiënt weer een tumor krijgt in de blaas na een operatie. 
In recente jaren heeft veel onderzoek zich gericht op het analyseren van de processen 
die zich in een tumorcel afspelen. Het in kaart brengen van deze processen kan 
misschien aangeven waarom een patiënt snel een tumor krijgt na een operatie, en een 
andere patiënt nooit meer. Bij het in kaart brengen van deze processen bestuderen 
onderzoekers zogenaamde moleculaire markers. Deze markers kunnen genen zijn 
waarvan de mRNA of eiwit expressie veranderd is of veranderingen in het DNA, 
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bijvoorbeeld mutaties in genen of het verdwijnen of vermenigvuldigen van delen van het 
DNA, die gewone gezonde cellen onderscheiden van kankercellen. Het gedrag van veel 
van deze markers lijkt bij patiënten met UCC en oppervlakkige tumoren de lengte van de 
recidiefvrije periode na de operatie te kunnen voorspellen. Helaas heeft geen enkele 
marker nog een toepassing gevonden in de kliniek. De belangrijkste drijfveer voor het 
onderzoek dat in dit proefschrift wordt gepresenteerd is de aanzienlijke vooruitgang die 
op het gebied van de voorspelling van de recidiefvrije periode bij patiënten met 
oppervlakkig UCC nog geboekt kan worden. Daarnaast is ook gekeken of er bij 
patiënten met oppervlakkige tumoren voorspeld kan worden of de ziekte in de toekomst 
erger wordt (tumorprogressie). Verder is ook onderzocht of de verandering van bepaalde 
moleculaire markers aan kan gegeven hoe lang een patiënt, met name die met invasieve 
tumoren (de T2, T3 en T4 tumoren), na een operatie nog in leven blijft. In het volgende 
deel van deze samenvatting zal een overzicht worden gegeven van de verschillende 
hoofdstukken in dit proefschrift. 
 De hoofdstukken 2, 3 en 4 beschrijven de voorspellende waarde van de moleculaire 
markers survivin, CDC91L1 en STK15 in patiënten met oppervlakkig en invasief UCC. 
In hoofdstuk 2 is mRNA expressie van het anti-apoptose gen survivin in tumorweefsel 
gemeten. Het weefsel was afkomstig van oppervlakkige en invasieve tumoren. Er werd 
een correlatie aangetoond tussen het survivin mRNA expressie niveau en toenemende 
maligniteit van de tumor, ofwel toenemend tumor stadium of graad. Bovendien lieten 
patiënten met snelle tumor recidieven een verhoogde survivin expressie in hun tumoren 
zien. Echter, het survivin mRNA expressie niveau voorspelde niet of een patiënt 
tumorprogressie ging ontwikkelen of vroeg zou overlijden. De resultaten geven aan dat 
survivin een nuttige marker kan zijn voor het voorspellen van tumor recidivering en 
mogelijk kan assisteren bij de besluitvorming omtrent het behandelen van patiënten met 
oppervlakkig UCC. 
Hoofdstuk 3 beschrijft de mRNA expressie van het gen CDC91L1 (PIG-U) in 
tumorweefsel van patiënten met verschillende stadia en gradaties van UCC. Een recent 
artikel uitgevoerd door Guo et al. (Nat. Med. 2004;10:374-381) schrijft een belangrijke 
oncogene werking toe aan dit gen bij blaaskanker. Deze onderzoekers vonden hogere 
expressie van CDC91L1 mRNA in 36% van de tumoren t.o.v. gezond weefsel, terwijl 
wij dit vonden in slechts 2,4% van de tumoren. Verder vertoonde de expressie van 
CDC91L1 geen enkele relatie met klinische parameters als recidivering, tumor 
progressie en overleving. Onze bevindingen aangaande CDC91L1 mRNA expressie in 
blaaskanker contrasteren met die van Guo et al. en maken verder onderzoek aan het 
expressie profiel van dit gen in deze ziekte noodzakelijk. Dit moet antwoord geven op de 
vraag of CDC91L1 nog steeds een interessante therapeutische target is in blaaskanker, 
zoals aangegeven door het onderzoek van Guo et al. 
De prognostische waarde van het T91A polymorfisme in het STK15 gen en de 
mRNA expressie van dit gen worden beschreven in hoofdstuk 4. Op DNA niveau is er 
Chapter 11 
 
128
voor het polymorfisme in het STK15 gen geen voorspellende waarde in de groep van 
patiënten aangetoond. Het STK15 mRNA expressie niveau daarentegen steeg naarmate 
de kwaadaardigheid van de tumoren toenam. Daarnaast hadden patiënten met hoge 
STK15 mRNA expressie in de tumoren een verhoogd risico om in het eerste jaar na de 
operatie een recidief te krijgen. Hoge STK15 expressie duidde ook op een verhoogd 
risico op tumorprogressie en een verlaagde overlevingskans. Het algemene beeld dat 
patiënten met hoge STK15 expressie in hun tumoren het slechter doen dan de patiënten 
met een lage expressie, maakt STK15 misschien interessant als therapeutische target. 
De relatie tussen survivin mRNA expressie en de tijd tot tumor recidivering, en het 
huidige gebrek aan een betrouwbare marker voor het voorspellen hiervan, bracht ons 
ertoe ons verder op dit specifieke onderzoeksveld te concentreren. We richtten ons op 
patiënten met Ta tumoren (de minst invasieve tumoren), omdat een groot deel van deze 
patiënten meerdere jaren vrij blijft van recidieven maar toch vaak vervelende controles 
van de blaas moet ondergaan. Dit draagt sterk bij aan de last voor de patiënt en aan de 
uitgaven voor behandeling. De hoofdstukken 5, 6 en 7 beschrijven de voorspelling van 
tumor recidivering bij patiënten met Ta tumoren. De analyse van de mRNA expressie 
van de genen die in hoofdstuk 5 is beschreven, is uitgevoerd als reactie op de cDNA 
microarray studie van Dyrskjøt et al. (Nat. Genet. 2003;33:90-96). Zij maakten 
onderscheid tussen patiënten met vroege of late recidieven m.b.v. een genpanel 
bestaande uit 26 genen. Wij hebben dit panel gevalideerd in een nieuwe groep patiënten 
met Ta UCC en korte of lange recidiefvrije perioden m.b.v. real-time kwantitatieve PCR. 
De overeenkomst tussen het expressieprofiel van Dyrskjøt et al. en dat van ons was 
verrassend slecht. Slechts 1 gen van de 26, HNRPK, vertoonde redelijk duidelijke 
verschillen in expressie tussen de twee patiëntengroepen, maar de prestaties v.w.b. de 
identificatie van patiënten met korte of lange recidiefvrije periodes liet te wensen over. 
Bovendien was het expressiepatroon tegengesteld aan het patroon van Dyrskjøt et al. 
Deze studie toont aan dat het erg belangrijk is om de resultaten van cDNA microarray 
analyses te valideren in aanvullende groepen patiënten en met andere technieken. 
In hoofdstuk 6 is de mRNA expressie van 23 genen, gemeten in dezelfde 44 primaire 
Ta tumoren die in hoofdstuk 5 zijn geanalyseerd, beschreven. De genen zijn geselecteerd 
na een zorgvuldige analyse van de literatuur en vertoonden een relatie met tumor 
recidivering in patiënten met UCC. Na statistische analyse liet alleen het gen survivin 
een significant verschillende expressie zien tussen de patiënten met een korte of een 
lange recidiefvrije periode. Het expressie patroon van survivin had een specificiteit van 
71% en een sensitiviteit van 70% voor de respectievelijke detectie van patiënten met een 
korte en een lange periode tot het eerste recidief na operatie. Bij een afkapwaarde van 
0,24 identificeerde survivin 52% van de patiënten die 4 jaar recidiefvrij blijven, zonder 
fout-negatieven te genereren. Deze resultaten zijn, in aanvulling op de bevindingen in 
hoofdstuk 2, ook een aanwijzing dat survivin een interessante marker kan zijn voor de 
voorspelling van de recidiefvrije periode in patiënten met UCC. 
Samenvatting 
 
129
In hoofdstuk 7 is SELDI-TOF massa spectrometrie gebruikt om van 33 van de 44 
tumoren die in de hoofdstukken 5 en 6 zijn gebruikt eiwitprofielen te genereren. De 
nauwkeurigheid van deze eiwitprofielen m.b.t. de identificatie van patiënten met korte of 
lange recidiefvrije periodes is vergeleken met die van de mRNA expressie profielen van 
de 49 genen die geanalyseerd zijn in de hoofdstukken 5 en 6. Eén van de eiwitpieken, 
met een gewicht van 33331 Da, geïdentificeerd m.b.v. SELDI-TOF MS vertoonde een 
even duidelijke verschillende expressie tussen de twee patiëntengroepen als survivin. 
Echter, de prestatie m.b.t. de identificatie van patiënten met een korte of lange 
recidiefvrije periode was slechter dan die van survivin. Ook liet de combinatie van 
survivin met eiwitpiek 33331 geen verbetering zien in de voorspelling van tumor 
recidivering. Toekomstige experimenten moeten bewijzen of de gelijktijdige analyse van 
hetzelfde tumorbiopt m.b.v. verschillende technieken een combinatie van markers op 
kan leveren die een betere prognostische voorspelling geven dan een marker 
afzonderlijk. 
Ten slotte evalueren de hoofdstukken 8 en 9 de bruikbaarheid van blaaswassingen 
voor het voorspellen van recidivering bij patiënten met oppervlakkig UCC. 
Blaaswassingen lijken een bruikbaar alternatief voor tumorweefsel, omdat ze aan kunnen 
geven of de blaas gezond is of dat zich er ziekteprocessen afspelen. Bovendien kunnen 
ze een toegevoegde waarde hebben t.o.v. weefsel, omdat ze de gehele binnenkant van de 
blaas bestrijken. Hoofdstuk 8 beschrijft de mRNA expressie van survivin in 
blaaswassingen die verrijkt zijn voor urotheelcellen om interferentie met de normalisatie 
van genexpressie door niet-urotheelcellen te voorkomen. Hoewel het survivin mRNA 
expressie niveau niet duidelijk correleerde met pathologische tumor stadium en graad, 
liet het wel een relatie met de tijd tot tumor recidivering zien. Dit gaf aan dat 
blaaswassingen gebruikt kunnen worden voor prognostische doeleinden en dat de 
noodzaak van het selecteren van tumorweefsel omzeild kan worden. 
Hoofdstuk 9 beschrijft de analyse van survivin en MKI67 mRNA expressie in een 
nieuwe verzameling blaaswassingen, afkomstig van patiënten met oppervlakkig UCC. In 
tegenstelling tot hoofdstuk 8, is de omvangrijke stap van urotheelcelverrijking 
weggelaten om de procedure te verkorten en te versimpelen. Dit kan de invoering in de 
kliniek vergemakkelijken. Ondanks de duidelijke correlatie tussen verhoogde survivin en 
MKI67 mRNA expressie en een hoger tumor stadium en graad, werd er geen relatie 
tussen hun mRNA niveau en de recidiefvrije periode gevonden. Dit zou toegewezen 
kunnen worden aan het weglaten van de verrijkingsstap of het wegvallen van een 
aanzienlijk aantal blaaswassingen (n=27) als gevolg van een slechte kwaliteit. Het laatste 
zou de samenstelling van de groep voor wat betreft recidivering beïnvloedt kunnen 
hebben. Aan de andere kant kan aan het mRNA expressie niveau van beide genen wel 
aangeven wat voor soort tumor er in de blaas zit. De bruikbaarheid van blaaswassingen 
voor de voorspelling van het ziekteverloop moet verder onderzocht worden. 
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De resultaten van het onderzoek tonen aan dat het mogelijk is om aan de hand van 
veranderingen van een moleculaire marker voorspellingen te kunnen doen over het 
verloop van de ziekte van patiënten met blaaskanker. Om deze moleculaire markers te 
kunnen gebruiken in de kliniek moet er nog veel aanvullend onderzoek gedaan worden. 
Voorlopig zal de uroloog nog vast moeten houden aan de beoordeling van het tumor 
stadium en de graad door de patholoog om te bepalen hoe de patiënt behandeld gaat 
worden. Echter, de voortdurende verbeteringen van de onderzoekstechnieken maken het 
waarschijnlijk dat moleculaire markers in de toekomst hun steentje bij zullen dragen aan 
de besluitvorming omtrent de behandeling van patiënten met blaaskanker. 
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Sandra, van Carla stelden in mijn promotie. Er ging haast geen bezoekje voorbij of er 
werd naar het wel en wee van mijn onderzoek geïnformeerd. Ik stelde dit erg op prijs en 
het werkte ook stimulerend. Bedankt! 
 
Lieve pap en mam, jullie hebben me altijd gesteund in mijn keuzes en het mogelijk 
gemaakt dat ik kon gaan studeren. Daarom heb ik bereikt waar ik nu ben. Ik hoop dat 
jullie trots op me zijn! Rienk en Luuk, jullie zijn twee toffe broers bij wie ik mijn 
promotie-sores ook altijd kwijt kon. Van mijn familie moet ik het zeker wel hebben! 
 
Allerliefste Carla. Ik leerde je kennen vlak voor mijn promotie. Je hebt me ontzettend 
fijn gesteund, je was er altijd voor me. Soms stimuleerde je me wel heel erg fanatiek: “Je 
moet wel goede publicaties halen hoor!” De heerlijke vakanties met jou deden me heel 
erg goed en ik kon daarna altijd weer met frisse moed verder. Op jou kan ik bouwen en 
dat voelt heel erg goed. Met jou wil ik naar de toekomst! 
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Iman Schultz werd geboren op 6 januari 1975 in Groningen. Na het VWO op het Wessel 
Gansfort College ging hij Biologie studeren aan de Rijksuniversiteit Groningen. Daar 
werd gekozen voor de moleculaire richting binnen de specialisatie Medische Biologie. 
De eerste stage werd gevolgd binnen de Disciplinegroep Klinische Immunologie onder 
leiding van Prof. dr. Lou de Leij. De directe begeleiders waren Dr. Wijnand Helfrich en 
Dr. Marcel van Kooij, waarvan de laatste werkzaam was op de Afdeling Medische 
Microbiologie. Het belangrijkste doel van de stage was de productie van het single-chain 
Fv antilichaam fragment MOC31, met specificiteit voor het kleincellig longcarcinoom 
geassocieerde eiwit EGP-2, door de gist Pichia pastoris. Daarna volgde een stage aan 
het Nederlands Kanker Instituut in Amsterdam. Binnen de afdeling Moleculaire 
Genetica werd onder leiding van Dr. Peter Demant en Dr. Nikos Tripodis gewerkt aan 
het in kaart brengen van een deel van chromosoom 6 van de muis waarin een gen zou 
liggen dat de gevoeligheid voor het krijgen van longkanker beïnvloedt. Na het behalen 
van het doctoraal diploma, werd negen maanden onderzoek gedaan op de afdeling 
Moleculaire Genetica van King’s College in Londen. Onder leiding van Dr. Ioannis 
Ragoussis werd een deel van humaan chromosoom 6, waarin een oncogen moest liggen 
dat een belangrijke rol zou spelen bij het ontstaan van botkanker, in kaart gebracht. Na 
deze onderzoeksperiode werd op 1 september 2001 begonnen met de promotie binnen de 
Afdeling Klinische Chemie van het Universitair Medisch Centrum St. Radboud in 
Nijmegen. Het onderzoek werd uitgevoerd onder leiding van Prof. Hans Willems, hoofd 
van de afdeling, Dr. Jacques de Kok en Dr. Dorine Swinkels. Begeleiding vanuit de 
Afdeling Urologie werd verzorgd door Prof. Fred Witjes. De resultaten van het 
promotieonderzoek zijn beschreven in dit proefschrift. 
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